Document:

Form of Warrant to Purchase Common Stock

 Exhibit 4.1 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO
THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 
 WARRANT TO PURCHASE STOCK 
  

					
	Company:	  	CADENCE PHARMACEUTICALS, INC., a Delaware corporation
	Number of Shares:	  	
                 
	  	
	Class of Stock:	  	Common Stock
	Warrant Price:	  	$3.79
	Issue Date:	  	December 22, 2011
	Expiration Date:	  	The 7th anniversary after the Issue Date
	Credit Facility:	  	This Warrant is issued in connection with the Second Amended and Restated Loan and Security Agreement dated as of December 22, 2011 among Oxford Finance LLC, Silicon
Valley Bank, General Electric Capital Corporation, and the Company (as amended from time to time, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, including without limitation the mutual
promises contained in the Loan Agreement
                    (“                    
;” together with any registered holder from time to time of this Warrant, “Holder”) is entitled to purchase the number of fully paid and nonassessable shares of common stock (the “Shares”) of the Company at the Warrant Price,
all as set forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. 
 ARTICLE 1. EXERCISE. 
 1.1 Method of Exercise. Holder may exercise this
Warrant by delivering a duly executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in Article 1.2, Holder shall also deliver to
the Company a check, wire transfer (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 

1.2 Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1, Holder may from time to time convert this
Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares
by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3. 
 1.3 Fair Market Value. If the Company’s common stock is traded in a public market, the fair market value of each Share shall be the closing price of a Share reported for the business day
immediately before Holder delivers its Notice of Exercise to the Company. If the 

 
Company’s common stock is not traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment. 

1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this Warrant and, if applicable, the
Company receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant representing the
Shares not so acquired. 
 1.5 Replacement of Warrants. On receipt of evidence reasonably satisfactory to the Company of
the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation on surrender and
cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 

1.6 Treatment of Warrant Upon Acquisition of Company. 
 1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale, license, or other disposition of all or substantially all of the assets of the Company, or
any reorganization, consolidation, or merger of the Company where the holders of the Company’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction.

 1.6.2 Treatment of Warrant at Acquisition. 
 A) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is not an asset sale and in which the sole consideration is cash, either (a) Holder shall exercise
its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will expire upon the
consummation of such Acquisition. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder may request in connection with such contemplated Acquisition
giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 
 B) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is an “arms length” sale of all or substantially all of the Company’s assets (and only
its assets) to a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”), either (a) Holder shall exercise its conversion or purchase right under this Warrant and such exercise will be deemed
effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will continue until the Expiration Date if the Company continues as a going concern following the closing of
any such True Asset Sale. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder may request in connection with such contemplated Acquisition giving
rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

C) Notwithstanding the foregoing provisions of this Section 1.6, in the event that the acquirer in an Acquisition does not agree to assume this
Warrant at and as of the closing thereof, this Warrant, to the extent not exercised or converted on or prior to such closing, shall 

 
terminate and be of no further force or effect as of immediately following such closing if all of the following conditions are met: (i) the acquirer is subject to the reporting requirements
of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, (ii) the class of stock or other security of the acquirer that would be received by Holder in connection with such Acquisition were Holder to exercise
or convert this Warrant on or prior to the closing thereof is listed for trading on a national securities exchange or approved for quotation on an automated inter-dealer quotation system, (iii) the value (determined as of the closing of such
Acquisition in accordance with the definitive agreements therefor) of the acquirer stock and/or other securities that would be received by Holder in respect of each Share were Holder to exercise or convert this Warrant on or prior to the closing of
such Acquisition is equal to or greater than one and one half (1.5) times the then-effective Warrant Price, and (iv) upon the exercise or conversion of this Warrant on or prior to the closing of such Acquisition, Holder would be able to
publicly resell all of the acquirer stock and/or other securities that would be received by Holder in such Acquisition within 120 days following the closing thereof pursuant to an effective registration statement covering such acquirer stock and/or
other securities or pursuant to the provisions of Rule 144 under the Act. 
 D) Upon the closing of any Acquisition other than those
particularly described in subsections (A), (B) and (C) above, the successor entity shall assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the
Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price and/or number of Shares shall be adjusted accordingly.

 As used herein “Affiliate” shall mean any person or entity that owns or controls directly or indirectly ten
(10) percent or more of the stock of Company, any person or entity that controls or is controlled by or is under common control with such persons or entities, and each of such person’s or entity’s officers, directors, joint venturers
or partners, as applicable. 
 ARTICLE 2. ADJUSTMENTS TO THE SHARES. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the Shares payable in common stock, or other
securities, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the
date the dividend occurred. If the Company subdivides the Shares by reclassification or otherwise into a greater number of shares or takes any other action which increases the amount of stock into which the Shares are convertible, the number of
shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the
Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 
 2.2
Reclassification, Exchange, Combinations or Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this
Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such
reclassification, exchange, substitution, or other event. The Company or its successor shall promptly issue to Holder an amendment to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or

 
conversion of this Warrant as a result of such reclassification, exchange, substitution or other event that results in a change of the number and/or class of securities issuable upon exercise or
conversion of this Warrant. The amendment to this Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the
Warrant Price and to the number of securities or property issuable upon exercise of the new Warrant. The provisions of this Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 

2.3 [Reserved.] 
 2.4 No Impairment. The Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out of all the
provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article against impairment; provided, however, that notwithstanding the foregoing, nothing in this
Section 2.4 shall restrict or impair the Company’s right to effect changes to the rights, preferences and privileges associated with the Shares with the requisite consent of the stockholders as may be required to amend the Certificate of
Incorporation from time to time so long as such amendment affects the rights, preferences and privileges granted to Holder associated with the Shares in the same manner as the other holders of common stock. 

2.5 Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of this Warrant and the number of Shares
to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount computed by
multiplying the fractional interest by the fair market value, as determined in accordance with Section 1.3, of a full Share. 
 2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such
adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the
Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price. 
 ARTICLE 3. REPRESENTATIONS AND
COVENANTS OF THE COMPANY. 
 3.1 Representations and Warranties. The Company represents and warrants and covenants to
the Holder as follows: 
 (a) Intentionally Omitted. 
 (b) All Shares which may be issued upon the exercise of the purchase right represented by this Warrant, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of
any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. 

 (c) Intentionally Omitted. 

3.2 No Stockholder Rights. Except as provided in this Warrant, the Holder will not have any rights as a stockholder of the Company
until the exercise of this Warrant. 
 3.3 Information. If the Company ceases to be a public company, then the Company
will provide information requested by Holder reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements. 
 ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents and warrants to the Company as follows: 
 4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by the Holder will be acquired for investment for the Holder’s account, not as a
nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that the Holder has not been formed for the specific purpose of acquiring this Warrant or the Shares. 

4.2 Disclosure of Information. The Holder has received or has had full access to all the information it considers necessary or
appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. The Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms
and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify
any information furnished to the Holder or to which the Holder has access. 
 4.3 Investment Experience. The Holder
understands that the purchase of this Warrant and its underlying securities involves substantial risk. The Holder has experience as an investor in securities of companies in the development stage and acknowledges that the Holder can bear the
economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or business matters that the Holder is capable of evaluating the merits and risks of its investment in
this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables the Holder to be aware of the
character, business acumen and financial circumstances of such persons. 
 4.4 Accredited Investor Status. The Holder is
an “accredited investor” within the meaning of Regulation D promulgated under the Act. 
 4.5 The Act. The
Holder understands that this Warrant and the Shares issuable upon exercise or conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide
nature of the Holder’s investment intent as expressed herein. The Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and
qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. 

 ARTICLE 5. MISCELLANEOUS. 
 5.1 Term. This Warrant is exercisable in whole or in part at any time and from time to time on or before the Expiration Date. 

5.2 Legends. This Warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if
any) shall be imprinted with a legend in substantially the following form: 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR
HYPOTHECATION IS EXEMPT FROM REGISTRATION. 
 5.3 Compliance with Securities Laws on Transfer. This Warrant and the
Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state
securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company
shall not require Holder to provide an opinion of counsel if the transfer is to any “affiliate” (as such term is defined in Regulation D promulgated under the Act) of Holder, provided that any such transferee is an “accredited
investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144, including, without limitation, the
availability of current information as referenced in Rule 144(c), Holder represents that it has complied with Rule 144(d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule 144(f), and the Company is
provided with a copy of Holder’s notice of proposed sale. 
 5.4 Transfer Procedure. After receipt by Holder of the
executed Warrant,                     may transfer all or part of this Warrant to one or more of
                    ’s affiliates (each, an
“                    Affiliate”), by execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of
Article 5.3 and upon providing the Company with written notice,                     , any such
                    Affiliate and any subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant
(or the Shares issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with any such transfer, the
                    Affiliate(s) or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name,
address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). The Company may refuse to transfer this Warrant or the Shares to any
person who directly competes with the Company, unless, in either case, the stock of the Company is publicly traded. 

 5.5 Notices. All notices and other communications from the Company to the Holder, or
vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may (or on the
first business day after transmission by facsimile) be, in writing by the Company or such Holder from time to time. Effective upon receipt of the fully executed Warrant and the initial transfer described in Article 5.4 above, all notices to the
Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 
  

			
		 	
                 

		 	              

		 	  

		 	Attn:
		 	Telephone:
		 	Facsimile:

 Notice to the Company shall be addressed as follows until the Holder receives notice of a change in address: 

Cadence Pharmaceuticals, Inc. 
 12481 High Bluff Drive, Suite 200 
 San Diego, CA 92130 

Attn: General Counsel 
 Telephone: (858) 436-1400 
 Facsimile: (858) 436-8510 

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 
 5.7
Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such
dispute, including reasonable attorneys’ fees. 
 5.8 Automatic Conversion upon Expiration. In the event that, upon
the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall
automatically be deemed on and as of such date to be converted pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised or converted, and the Company shall promptly deliver
a certificate representing the Shares (or such other securities) issued upon such conversion to the Holder. 
 5.9
Counterparts. This Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement. 
 5.10 Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law.

									
	 “COMPANY”
  

CADENCE PHARMACEUTICALS, INC.
	 		 		 	
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

		 	(Print)	 		 		 	(Print)
	 Title:
	 	 Chairman of the Board, President or
 Vice President
	 		 	 Title:
	 	 Chief Financial Officer, Secretary,

Assistant Treasurer or Assistant

Secretary

  

			
	 “HOLDER”

	
	  

		
	By:	 	  

		
	Name:	 	  
 (Print)

	Title:	 	  

 APPENDIX 1 
 NOTICE OF EXERCISE 
 1. Holder elects to purchase
                     shares of the Common Stock of CADENCE PHARMACEUTICALS, INC. pursuant to the terms of the attached Warrant, and tenders payment
of the purchase price of the shares in full. 
 [or] 
 1. Holder elects to convert the attached Warrant into Shares/cash [strike one] in the manner specified in the Warrant. This conversion is exercised for
             of the Shares covered by the Warrant. 
 [Strike
paragraph that does not apply.] 
 2. Please issue a certificate or certificates representing the shares in the name specified
below: 
  

	
	                             
                                         
                                         
   
	 Holders Name

	
	
                        
                                         
                                         
        

	
	
                        
                                         
                                         
        

	 (Address)

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Article 4 of the Warrant as the date hereof. 
  

	
	 HOLDER:

	
	
                        
                                         
                                      

	
	
By:                       
                                         
                                

	
	
Name:                       
                                         
                          

	
	
Title:                       
                                         
                            

	
	
(Date):                       
                                         
                         

 APPENDIX 2 
 ASSIGNMENT 
 For value received,
                     hereby sells, assigns and transfers unto 
  

			
	Name:	  	  

		
	Address:	  	  

		
	Tax ID:	  	  

 that certain Warrant to Purchase Stock issued by CADENCE PHARMACEUTICALS, INC. (the “Company”),
on December 22, 2011 (the “Warrant”) together with all rights, title and interest therein. 
  

			
		 	                             
                                         
                                         
             
		
		 	By:                            
                                         
                                         
       
		
		 	Name:                            
                                         
                                         
 
		
		 	Title:                            
                                         
                                         
   
		
	Date:                     	 	

 By its execution below, and for the benefit of the Company,
[                    ] makes each of the representations and warranties set forth in Article 4 of the Warrant and agrees to all other provisions of
the Warrant as of the date hereof. 
  

	
	[                             
                                         
                              ]
	
	By:                             
                                         
                          
	
	Name:                             
                                         
                    
	
	Title:Second Amended and Restated Loan and Security Agreement

 Exhibit 10.1 
 SECOND AMENDED AND RESTATED 
 LOAN AND SECURITY AGREEMENT 

THIS SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Agreement”) dated December 22, 2011 by and
among OXFORD FINANCE LLC, successor-in-interest to Oxford Finance Corporation (“Oxford”), Oxford in its capacity as collateral agent on behalf of the Lenders (the “Collateral Agent”); SILICON VALLEY BANK, a
California-chartered bank, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 (“SVB”); GENERAL ELECTRIC CAPITAL CORPORATION (as successor-by-assignment to GE Business Financial Services Inc.)
(“GECC”) (Oxford, SVB and GECC, each a “Lender” and collectively “Lenders”); and CADENCE PHARMACEUTICALS, INC., a Delaware corporation, whose address is 12481 High Bluff Drive, Suite 200, San Diego,
California 92130 (“Borrower”) provides the terms on which Lenders shall lend to Borrower and Borrower shall repay Lenders. 
 Borrower, Lenders and Collateral Agent entered into that certain Amended and Restated Loan and Security Agreement dated as of June 18, 2010, as amended by that certain First Amendment to Amended and
Restated Loan and Security Agreement dated as of November 22, 2010 and as further amended by that certain Second Amendment to Amended and Restated Loan and Security Agreement dated as of March 31, 2011 (as amended, restated, or otherwise
modified from time to time, the “Original Agreement”) pursuant to which Lenders agreed to extend and make available to Borrower certain advances of money. Borrower, Lenders and Collateral Agent wish to restate the terms of the
Original Agreement pursuant to the terms hereof. The parties agree as follows: 
  

	 	1.	ACCOUNTING AND OTHER TERMS 

 Accounting terms not defined in this Agreement shall be construed following GAAP. Calculations and determinations must be made following GAAP. The term “financial statements” includes the notes
and schedules. The terms “including” and “includes” always mean “including (or includes) without limitation,” in this or any Loan Document. Capitalized terms in this Agreement shall have the meanings as set forth in
Section 13. All other terms contained in this Agreement, unless otherwise indicated, shall have the meanings provided by the Code, to the extent such terms are defined therein. 

 

	 	2.	LOANS AND TERMS OF PAYMENT 

 2.1 Promise to Pay. Borrower will pay Lenders the unpaid principal amount of all Credit Extensions hereunder with all interest, fees and finance charges due thereon as and when due in accordance
with this Agreement. 
 2.1.1 Additional Growth Capital Loan Facility. 

(a) Availability. Subject to the terms and conditions of this Agreement, Lenders agree, severally and not jointly, to make an
additional Growth Capital Advance to Borrower on the Effective Date (the “Additional Growth Capital Advance”) in the aggregate amount of the Growth Capital Loan Commitment less the aggregate outstanding principal amount of the
Existing Growth Capital Advances according to each Lender’s pro rata share of the Growth Capital Loan Commitment (based upon the respective Growth Capital Commitment Percentage of each Lender). For the avoidance of doubt, (i) Oxford’s
portion of the Additional Growth Capital Advance shall be Two Million Two Hundred Twenty-Five Thousand Eight Hundred Fifty-Four Dollars and 32/100 ($2,225,854.32), (ii) SVB’s portion of the Additional Growth Capital Advance shall be Eight
Hundred Fifteen Thousand Nine Hundred Ninety-Eight Dollars and 35/100 ($815,998.35) and (iii) GECC’s portion of the Additional Growth Capital Advance shall be One Million Four Hundred Nine Thousand Six Hundred Eighty-Three Dollars and
69/100 ($1,409,683.69) (each of the foregoing amounts, such Lender’s “Additional Growth Capital Amount” respectively). When repaid, the Additional Growth Capital Advance may not be re-borrowed. 

(b) Borrowing Procedure. To obtain the Additional Growth Capital Advance, Borrower must deliver to Lenders a completed
Disbursement Letter in the form attached as Exhibit B-1 and to SVB a completed Loan Payment/Advance Request Form in the form attached as Exhibit B-2. In addition, Secured Promissory Notes payable to each Lender in accordance with
Section 2.3 must be signed by a Responsible Officer or designee and delivered to the applicable Lenders. On the Additional Growth Capital Funding Date, each Lender shall credit and/or transfer (as applicable) to Borrower’s deposit
account, an amount equal to its Additional Growth Capital Amount less such Lender’s portion of the Existing Final Payment, all in accordance with the Disbursement Letter. 

  
 1 

 2.1.2 Existing Growth Capital Advance. As of the Effective Date, under the Original
Agreement, there are existing loans outstanding in the aggregate principal amount of Twenty-Five Million Five Hundred Forty-Eight Thousand Four Hundred Sixty-Three Dollars and 64/100 ($25,548,463.64) (collectively, the “Existing Growth
Capital Advances”), and accrued but unpaid interest thereon in an aggregate amount equal to One Hundred Sixty-Two Thousand Six Hundred Sixty-One Dollars and 12/100 ($162,661.12). For the avoidance of doubt, (a) Oxford’s portion of
the Existing Growth Capital Advances is Twelve Million Seven Hundred Seventy-Four Thousand One Hundred Forty-Five Dollars and 68/100 ($12,774,145.68) and Oxford’s portion of the accrued interest as of the Effective Date is Eight-One Thousand
Three Hundred Twenty-Six Dollars ($81,326.52), (b) SVB’s portion of the Existing Growth Capital Advances is Four Million Six Hundred Eighty-Three Thousand One Dollars and 65/100 ($4,683,001.65) and SVB’s portion of accrued interest as
of the Effective Date is Twenty-Nine Thousand Eight Hundred Sixteen Dollars and 85/100 ($29,816.85) and (c) GECC’s portion of the Existing Growth Capital Advances is Eight Million Ninety-One Thousand Three Hundred Sixteen Dollars and
31/100 ($8,091,316.31) and GECC’s portion of accrued interest as of the Effective Date is Fifty-One Thousand Five Hundred Seventeen Dollars and 75/100 ($51,517.75). 
 2.2 Repayment of Credit Extensions on Growth Capital Advances. 
 (a)
Principal and Interest Payments on Payment Dates. 
 (i) Growth Capital Advances. Borrower shall make monthly
payments of interest only in respect of the Growth Capital Advances commencing on January 1, 2012 and continuing thereafter on the first Business Day of each successive calendar month during the Growth Capital Interest Only Period. Commencing
on the Growth Capital Amortization Date, Borrower shall make thirty (30) equal monthly payments of principal and interest which would fully amortize the outstanding Growth Capital Advances as of the Growth Capital Amortization Date over the
Growth Capital Repayment Period and on the first Business Day of each successive month and continuing thereafter during the Growth Capital Repayment Period on the first Business Day of each successive calendar month. All unpaid principal and accrued
interest is due and payable in full on the Growth Capital Maturity Date. A Growth Capital Advance may only be prepaid in accordance with Sections 2.2(d) and 2.2(e). 

(ii) Payments received as to a Growth Capital Advance after 12:00 noon Pacific time are considered received at the opening of business
on the next Business Day. 
 (b) Interest Rate. 

(i) Growth Capital Advances. As of the Effective Date and subject to Section 2.2(b)(ii), the outstanding principal
amount of the Growth Capital Advances shall accrue interest at a fixed per annum rate equal to ten and ninety-nine one hundredths percent (10.99%) (the “Basic Rate”), which interest shall be payable monthly in accordance with
Section 2.2(a). Interest shall accrue on the Growth Capital Advances for the day on which the Growth Capital Advance is made, and shall accrue on the Growth Capital Advance, or any portion thereof, for the day on which the Growth Capital
Advance or such portion is paid. Interest is computed on the basis of a 360 day year of twelve 30-day months. 
 (ii)
Default Rate. The Growth Capital Advances shall bear interest at a per annum rate equal to the Default Rate during the continuance of an Event of Default. 
 (c) Growth Capital Final Payment. On the earlier of (i) the Growth Capital Maturity Date, (ii) any prepayment of the Growth Capital Advances, or (iii) the acceleration of the Growth
Capital Advances, Borrower shall pay, in addition to the outstanding principal, accrued and unpaid interest, and all other amounts due on such date with respect to the Growth Capital Advances, an amount equal to the Growth Capital Final Payment
(which shall be in addition to the Existing Final Payment set forth in Section 2.4(c)). 
 (d) Mandatory
Prepayment Upon an Acceleration. If the Growth Capital Advances are accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to Collateral Agent for the ratable accounts of the Lenders an amount equal to the
sum of: (i) all outstanding principal plus accrued interest, plus (ii) the Growth Capital Final Payment, plus (iii) the Prepayment Fee, plus (iv) all other sums, if any, that shall have become due and payable, including interest
at the Default Rate with respect to any past due amounts. 
 (e) Permitted Prepayment of Loans. Borrower shall have the
option to prepay all, but not less than all, of the Growth Capital Advances advanced by Lenders under this Agreement, provided Borrower (i) provides 

  
 2 

 
written notice to Lenders of its election to prepay the Growth Capital Advances at least thirty (30) days prior to such prepayment, and (ii) pays, on the date of such prepayment
(A) all outstanding principal plus accrued interest, plus (B) the Prepayment Fee (except as provided in Section 7.3), plus (C) the Growth Capital Final Payment, plus (D) all other sums, if any, that shall have become
due and payable, including interest at the Default Rate with respect to any past due amounts. 
 (f) Debit of Accounts.
SVB may debit any of Borrower’s deposit accounts for principal and interest payments or any other amounts Borrower owes SVB hereunder, when due and payable. These debits shall not constitute a set-off. Borrower shall separately set up an ACH
payment structure in favor of Oxford and GECC, satisfactory to Oxford and GECC, respectively. 
 2.3 Secured Promissory
Notes. Each Lender’s Additional Growth Capital Amount and Existing Growth Capital Advances shall be evidenced by a Secured Promissory Note or Notes (or, as elected by any Lender, amended and restated Notes) in substantially the form
attached as Exhibit D hereto (each of the foregoing, a “Secured Promissory Note”), and shall be repayable as set forth herein. Notwithstanding the foregoing, if any Lender elects to replace any promissory note relating to the
Existing Growth Capital Advances and entered into prior to the Effective Date (each, an “Existing Note”) with a Secured Promissory Note made in favor of such Lender as of the Effective Date, such Lender shall within ten
(10) Business Days following the Effective Date, return to Borrower the previously issued Existing Note marked “cancelled” or shall provide satisfactory evidence to Borrower of such cancellation (and deliver an electronic version of
such cancelled Existing Note to Borrower on the Effective Date). Borrower irrevocably authorizes each Lender to, and subject to the terms and conditions set forth herein, Lender shall make or cause to be made, on or about the funding date of each
Growth Capital Advance or at the time of receipt of any payment of principal on such Lender’s Secured Promissory Note, an appropriate notation on such Lender’s Secured Promissory Note Record reflecting the making of such Lender’s
portion of such Growth Capital Advance or (as the case may be) the receipt of such payment, which payment shall be applied ratably among each Lender’s Secured Promissory Notes if there are more than one in favor of such Lender. The outstanding
amount of the Growth Capital Advances set forth on such Lender’s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender, but the failure to record, or any error in so
recording, any such amount on such Lender’s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower hereunder or under any Secured Promissory Note to make payments of principal of or interest on any
Secured Promissory Note when due. Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note. Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note
in the same principal amount thereof and of like tenor. 
 2.4 Fees. Borrower will pay to Lenders: 

(a) Prepayment Fee. The Prepayment Fee, as defined herein, if and when applicable. 

(b) Growth Capital Final Payment. The Growth Capital Final Payment, when due hereunder. 

(c) Existing Growth Capital Advances Final Payment. Lenders shall withhold from the disbursement of the Additional Growth Capital
Advance an amount equal to their respective pro-rata amounts in accordance with their respective Growth Capital Commitment Percentages (as defined under the Original Agreement) owing by Borrower for the accrued portion of the Final Payment (as
defined under the Original Agreement in the aggregate amount of Nine Hundred Fifty-Four Thousand Three Hundred Fifteen Dollars and 28/100 ($954,315.28) (the “Existing Final Payment”), all in accordance with the Disbursement Letter.
For the avoidance of doubt, (a) Oxford’s portion of the Existing Final Payment is Four Hundred Thirty-Four Thousand Five Hundred Thirty-One Dollars and 50/100 ($434,531.50), (b) SVB’s portion of the Existing Final Payment is One
Hundred Eighty-Two Thousand One Hundred Forty-Seven Dollars and 97/100 ($182,147.90) and (c) GECC’s portion of the Existing Final Payment is Three Hundred Thirty-Seven Thousand Six Hundred Thirty-Five Dollars and 88/100 ($337,635.88).

 (d) Lenders Expenses. All Lenders Expenses (including reasonable attorneys’ fees and reasonable expenses, which
fees and expenses for documentation and negotiation of this Agreement and the transactions contemplated hereby shall not to exceed $75,000 through the Effective Date without the prior written consent of Borrower) incurred through and after the
Effective Date, when due. 
 2.5 (a) Payments Free of Taxes. Payments received by Lenders from Borrower hereunder
will be made free and clear of any U.S. federal withholding taxes, except as required pursuant to applicable law, regulation or treaty. If Borrower is required to make any such withholding or deduction from any such payment or other sum payable

  
 3 

 
hereunder to Lenders, Borrower hereby covenants and agrees (i) to make such withholding or deduction, (ii) to pay the full amount withheld or deducted to the relevant Governmental
Authority and (iii) that the amount due from Borrower with respect to such payment or other sum payable hereunder will be increased to the extent necessary to ensure that, after the making of such required withholding or deduction, each Lender
receives a net sum equal to the sum which it would have received had no withholding or deduction been required. Borrower will, upon request, furnish Lenders with a copy of a receipt issued by such Governmental Authority or other proof reasonably
satisfactory to Lenders indicating that Borrower has made such withholding payment; provided, however, that Borrower need not make any withholding payment if the amount or validity of such withholding payment is contested in good faith by
appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrower. The agreements and obligations of Borrower contained in this Section 2.5 shall survive the termination of this Agreement.

 (b) Status of Lenders. Each Lender (and any Person to which any Lender transfers an interest in this Agreement) agrees
that on the date such Lender or Person becomes a party to or acquires an interest this Agreement, it will deliver to the Borrower and the Collateral Agent either (i) if such Lender or Person is a “United States person” as defined in
Section 7701(a)(30) of the IRC, two duly and appropriately completed copies of a United States Internal Revenue Service Form W-9 or any successor applicable form or (ii) if such Lender or Person is not a United States person, two duly and
appropriately completed copies of United States Internal Revenue Service Form W-8ECI, W-8EXP, W-8BEN (including, in the case of any Lender claiming a portfolio interest exemption, a certificate reasonably satisfactory to Borrower and Collateral
Agent, to the effect that such Lender or Person is not a bank for purposes Section 881(c) of the IRC, is not a 10-percent shareholder (within the meaning of Section 871(h)(3)(B) of the IRC) of the Borrower and is not a controlled foreign
corporation related to the Borrower (within the meaning of Section 864(d)(4) of the IRC)) or W-8IMY (together with the required attachments), or successor applicable form, as the case may be, claiming therein, to the extent permissible under
applicable law, a reduction in or an exemption from United States withholding taxes, and, if reasonably requested by Borrower or Collateral Agent any additional statements and forms required by law to establish a Lender’s or Person’s
eligibility for such a reduction or exemption. Each such Lender or Person agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall promptly update such form or certification
or promptly notify the Borrower and the Collateral Agent in writing of its legal inability to do so. 
  

	 	3.	CONDITIONS OF LOANS 

3.1 Conditions Precedent to Initial Credit Extension. The Lenders’ agreement to make the initial Credit Extension is subject
to the condition precedent that Lenders shall have received, in form and substance satisfactory to Lenders, such documents and completion of such other matters, as Lenders may reasonably deem necessary or appropriate, including, without limitation,
the following: 
 (a) this Agreement duly executed by each party hereto; 

(b) the Operating Documents of Borrower and good standing certificates of Borrower certified by the Secretary of State of Borrower’s
state of organization and each state in which Borrower is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date; 
 (c) a certificate of the Secretary of Borrower with respect to articles, by-laws, incumbency and resolutions authorizing the execution and delivery of this Agreement; 

(d) Perfection Certificate by Borrower, together with the duly executed original signature thereto; 

(e) Collateral Agent shall have received certified copies, dated as of a recent date, of financing statement searches with respect to
Borrower, as Lenders shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements constitute Permitted Liens; 

(f) new Control Agreements covering each of Borrower’s deposit accounts and securities accounts; 

(g) an amendment to the DDN bailee agreement reflecting Borrower’s current address, duly executed by DDN; 

  
 4 

 (h) a legal opinion of Borrower’s counsel dated as of the Effective Date together with
the duly executed original signature thereto; 
 (i) a copy of Borrower’s Investors’ Rights Agreement and Voting
Agreement and any amendments thereto, which Lenders acknowledge have been provided by Borrower prior to the Effective Date; 

(j) Borrower shall have delivered evidence satisfactory to Collateral Agent that the insurance policies required by
Section 6.5 hereof are in full force and effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Collateral Agent; 

(k) duly executed original signature to the Oxford Warrant; 
 (l) duly executed original signature to the SVB Warrant; 
 (m) duly executed
original signature to the GECC Warrant (such Warrant to be issued to GECC’s Affiliate, GE Capital Equity Investments, Inc. at GECC’s direction); 
 (n) payment of the fees and Lenders Expenses then due specified in Section 2.4 hereof; 
 (o) a Post-Closing Agreement executed by each party hereto, and 
 (p) such other
documents, and completion of such other matters, as Lenders may reasonably deem necessary or appropriate. 
 3.2 Conditions
Precedent to all Credit Extensions. The obligations of Lenders to make each Credit Extension, including the initial Credit Extension, is subject to the following: 
 (a) receipt by the Lenders of an executed Disbursement Letter in the form of Exhibit B-1 attached hereto; and (ii) SVB of an executed Loan Payment/Advance Request Form in the form of
Exhibit B-2 attached hereto; 
 (b) Borrower shall have duly executed and delivered to each Lender a Secured Promissory
Note in accordance with Section 2.3, and Warrants to Purchase Stock (if applicable); and 
 (c) the representations
and warranties in Section 5 shall be true in all material respects on the date of the Disbursement Letter and Loan Payment/Advance Request Form, and on the effective date of each Credit Extension and no Event of Default shall have
occurred and be continuing, or result from the Credit Extension. Each Credit Extension is Borrower’s representation and warranty on that date that the representations and warranties in Section 5 remain true in all material respects.
Any materiality qualifier contained in the foregoing shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof. 

 

	 	4.	CREATION OF SECURITY INTEREST 

 4.1 Grant of Security Interest. Borrower hereby grants to Collateral Agent, for the ratable benefit of each Lender, to secure the payment and performance in full of all of the Obligations and the
performance of each of Borrower’s duties under the Loan Documents, a continuing security interest in, and pledges and assigns to Collateral Agent, for the ratable benefit of each Lender, the Collateral, wherever located, whether now owned or
hereafter acquired or arising, and all proceeds and products thereof. Borrower warrants and represents that the security interest granted herein shall be a first priority security interest in the Collateral. SVB may place a “hold” on any
certificates of deposit or deposit or investment accounts pledged as Collateral to secure cash management services, corporate business credit cards or letters of credit separately issued or supplied by SVB under separate agreements between SVB and
Borrower. 
 Borrower acknowledges that it previously has entered, and/or may in the future enter, into Bank Services Agreements
with SVB. Regardless of the terms of any Bank Services Agreement, Borrower agrees that any amounts Borrower owes SVB thereunder shall be deemed to be Obligations hereunder and that it is the intent of Borrower and SVB to have all such Obligations
secured by the continuing security interest in the Collateral granted herein (subject only to Permitted Liens that expressly have superior priority to Collateral Agent’s Lien in this Agreement). 

  
 5 

 Borrower agrees that any disposition of the Collateral in violation of this Agreement, by
either the Borrower or any other Person, shall be deemed to violate the rights of the Lenders under the Code. If Borrower shall at any time, acquire, assert or file a commercial tort claim, Borrower shall promptly notify Lenders in a writing signed
by Borrower of the brief details thereof and grant to Collateral Agent, for the ratable benefit of Lenders, in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in
form and substance reasonably satisfactory to Lenders. 
 If this Agreement is terminated, Collateral Agent’s Lien in the
Collateral shall continue until the Obligations (other than inchoate indemnity obligations) are repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as the Lenders’
obligation to make Credit Extensions has terminated, Collateral Agent shall, at Borrower’s sole cost and expense, promptly (a) terminate the security interest in the Collateral granted by Borrower to Collateral Agent for the benefit of the
Lenders in connection with the Growth Capital Advances, and (b) execute and/or file, as applicable, all documents and other instruments required to terminate such security interest (or grant Borrower the authority to file all documents and
other instruments required to terminate such security interests, as applicable) and upon such termination all rights in the Collateral shall revert to Borrower. In the event (i) all Obligations (other than inchoate indemnity obligations),
except for Bank Services, are repaid in full in cash, and (ii) this Agreement and the Lenders’ obligation to make Credit Extensions is terminated, Collateral Agent shall terminate the security interest in the Collateral granted by Borrower
to Collateral Agent for the benefit of the Lenders in connection with the Growth Capital Advances and execute and/or file, as applicable, all documents and other instruments required to terminate such security interest (or grant Borrower the
authority to file all documents and other instruments required to terminate such security interests, as applicable) upon Borrower providing cash collateral acceptable to SVB in its good faith business judgment for Bank Services, if any. In the event
such Bank Services consist of outstanding Letters of Credit, Borrower shall provide to SVB cash collateral in an amount equal to (A) one hundred five percent (105.0%) of the face amount of all such Letters of Credit denominated in Dollars
and (B) one hundred ten percent (110.0%) of the Dollar Equivalent of the face amount of all such Letters of Credit denominated in a Foreign Currency plus, in each case, all interest, fees, and costs due or to become due in connection
therewith (as estimated by SVB in its good faith business judgment), to secure all of the Obligations relating to such Letters of Credit. 
 4.2 Authorization to File Financing Statements. Borrower hereby authorizes Collateral Agent and each Lender to file financing statements, without notice to Borrower, with all appropriate
jurisdictions, in order to perfect or protect Collateral Agent’s and Lenders’ interest or rights hereunder. As of the date of this Agreement, Collateral Agent and Lenders are not currently contemplating recording any fixture filings with
the applicable recording office, but reserve their right to do so. Collateral Agent and Lenders acknowledge that, to the extent Borrower has any fixtures, Collateral Agent and Lenders may need to file a real property related financing statement
under section 9-502(b) of the Code for their security interests to have priority over certain conflicting interests in such fixtures. 
 4.3 Account Control. Unless an Event of Default has occurred and is continuing, Collateral Agent hereby agrees that: (a) it will not send a “notice of control” under any applicable
account control agreements, and (b) as to accounts maintained by it, it shall not place a “hold” on any such accounts, except SVB may place a “hold” on any certificates of deposit or deposit or investment accounts pledged as
Collateral to secure cash management services, corporate business credit cards or letters of credit separately issued or supplied by SVB under separate agreements between SVB and Borrower. 

 

	 	5.	REPRESENTATIONS AND WARRANTIES 

 Borrower represents and warrants to Collateral Agent and each Lender as follows: 

5.1 Due Organization and Authorization. Borrower and each of its Subsidiaries is duly existing and in good standing in its state
of formation and qualified and licensed to do business in, and in good standing in, any state in which the conduct of its business or its ownership of property requires that it be qualified, except where the failure to do so could not reasonably be
expected to cause a Material Adverse Change. In connection with this Agreement, the Borrower delivered to Lenders a certificate signed by the Borrower and entitled “Perfection Certificate”. The Borrower represents and warrants to
Collateral Agent and each Lender that: (a) the Borrower’s exact legal name is that indicated on the Perfection Certificate and on the signature page hereof; (b) the Borrower is an organization of the type, and is organized in the
jurisdiction, set forth in the Perfection Certificate; (c) the Perfection Certificate accurately sets forth the Borrower’s organizational identification number or accurately states that the Borrower has none; (d) the Perfection
Certificate accurately sets forth the Borrower’s place of business, or, if more than one, its chief executive office as well as the Borrower’s mailing address if different, and (e) all other information set forth on the Perfection
Certificate 

  
 6 

 
pertaining to the Borrower is accurate and complete. If the Borrower does not now have an organizational identification number, but later obtains one, Borrower shall forthwith notify the Lenders
of such organizational identification number. 
 The execution, delivery and performance of the Loan Documents have been duly
authorized, and do not conflict with Borrower’s certificate of incorporation or bylaws, nor constitute an event of default under any material agreement by which Borrower is bound, nor contravene any provision of any federal, state or other
applicable statute, rule or regulation applicable to Borrower nor require any governmental orders, permissions, consents, approvals or authorizations and when executed and delivered will be valid and binding obligations of the Borrower, enforceable
against Borrower in accordance with their terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights and general principles of equity
that restrict the availability of equitable or legal remedies. Borrower is not in default under any agreement to which or by which it is bound in which the default would reasonably be expected to cause a Material Adverse Change. 

5.2 Collateral. Borrower has rights in and good title to the Collateral, free of Liens except Permitted Liens. Borrower has no
deposit account, other than the deposit accounts with SVB and deposit accounts described in the Perfection Certificate delivered to Lenders in connection herewith. The Accounts are bona fide, existing obligations, and the service or property has
been performed or delivered to the account debtor or its agent for immediate shipment to and unconditional acceptance by the account debtor. Except as described in the Perfection Certificate, the Collateral is not in the possession of any third
party bailee (such as a warehouse). Except as hereafter disclosed to the Lenders in writing by Borrower, none of the components of the Collateral shall be maintained at locations other than as provided in the Perfection Certificate. In the event
that Borrower, after the date hereof, intends to store or otherwise deliver any portion of the Collateral to a bailee, then Borrower will first receive the written consent of Lenders and such bailee must acknowledge in writing that the bailee is
holding such Collateral for the benefit of Collateral Agent acting for Lenders; All Inventory is in all material respects of good and marketable quality, free from material defects, other than Inventory consisting of clinical trial material which is
usable as contemplated. Borrower is the sole owner or exclusive licensee of the Intellectual Property. Each Patent is valid and enforceable and no part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and
no claim has been made that any part of the Intellectual Property violates the rights of any third party, except to the extent such claim would not reasonably be expected to cause a Material Adverse Change. 

5.3 Litigation. Except as shown in the Perfection Certificate, there are no actions or proceedings pending or, to the knowledge of
Borrower’s Responsible Officers, threatened by or against Borrower or any of its Subsidiaries in which an adverse decision would reasonably be expected to cause a Material Adverse Change. 

5.4 No Material Deterioration in Financial Statements. All consolidated financial statements for Borrower, and any of its
Subsidiaries, delivered to Lenders fairly present in all material respects Borrower’s consolidated financial condition and Borrower’s consolidated results of operations. There has not been any material deterioration in Borrower’s
consolidated financial condition since the date of the most recent financial statements submitted to Lenders, although Borrower’s cash may have declined to pay necessary and ordinary course business expenses. 

5.5 Solvency. The fair salable value of Borrower’s assets (including goodwill minus disposition costs) exceeds the fair value
of its liabilities; Borrower is not left with unreasonably small capital after the transactions in this Agreement; and Borrower is able to pay its debts (including trade debts) as they mature. 

5.6 Regulatory Compliance. Borrower is not an “investment company” or a company “controlled” by an
“investment company” under the Investment Company Act. Borrower is not engaged as one of its important activities in extending credit for margin stock (under Regulations T and U of the Federal Reserve Board of Governors). Borrower has
complied in all material respects with the Federal Fair Labor Standards Act. Borrower has not violated any laws, ordinances or rules, the violation of which would reasonably be expected to cause a Material Adverse Change. None of Borrower’s or
any Subsidiary’s properties or assets has been used by Borrower or any Subsidiary or, to the best of Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than
legally or the violation of which would not reasonably be expected to cause a Material Adverse Change. Borrower and each Subsidiary has timely filed (within any applicable extension period) all required tax returns and paid, or made adequate
provision to pay, all material taxes, except those being contested in good faith with adequate reserves under GAAP. Borrower and each Subsidiary has obtained all consents, approvals and authorizations of, made all declarations or filings with, and
given all notices to, all government authorities that are necessary to continue its business as currently conducted, except where the failure to make such declarations, notices or filings would not reasonably be expected to cause a Material Adverse
Change. 

  
 7 

 5.7 Subsidiaries. Borrower does not own any stock, partnership interest or other
equity securities except for Permitted Investments. 
 5.8 Full Disclosure. No written representation, warranty or other
statement of Borrower in any certificate or written statement given to Collateral Agent or any Lender (taken together with all such written certificates and written statements given to Collateral Agent or any Lender) contains any untrue statement of
a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading, as of the date of such representation, warranty or other statement, it being recognized by Collateral
Agent and Lenders that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may
differ from the projected or forecasted results. 
  

	 	6.	AFFIRMATIVE COVENANTS 

 Borrower
shall do all of the following for so long as any Lender has an obligation to make any Credit Extension, or there are outstanding Obligations: 
 6.1 Government Compliance. Borrower shall maintain its and all of its Subsidiaries’ legal existence and good standing in their respective jurisdictions of formation and maintain qualification
in each jurisdiction in which the failure to so qualify would reasonably be expected to cause a Material Adverse Change. Borrower shall comply, and have each of its Subsidiaries comply, with all laws, ordinances and regulations to which it is
subject (including, without limitation, laws and regulations enforced by the U.S. Food and Drug Administration (“FDA”), noncompliance with which would reasonably be expected to cause a Material Adverse Change. 

6.2 Financial Statements, Reports, Certificates. Borrower shall deliver to Lenders: (i) as soon as available, but no later
than forty-five (45) days after the last day of each quarter, a company prepared consolidated balance sheet and income statement covering Borrower’s consolidated operations during the period certified by a Responsible Officer and in a form
acceptable to Lenders; (ii) copies of Borrower’s quarterly financial statements including a balance sheet, income statement and statement of cash flows, each prepared by Borrower in accordance with GAAP consistently applied by Borrower
(not including footnotes required under GAAP) and certified by Borrower’s Chief Financial Officer within forty-five (45) days after the close of each of Borrower’s first three fiscal quarters; (iii) as soon as available, but no
later than one hundred eighty (180) days after the last day of Borrower’s fiscal year, audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion on the financial statements
from an independent certified public accounting firm reasonably acceptable to Lenders; and (iv) annual financial projections approved by Borrower’s Board of Directors consistent in form and detail with those provided to Borrower’s
venture capital investors as soon as available, but no later than forty-five (45) days after the last day of Borrower’s fiscal year. 
 (a) Borrower shall deliver to Lenders, within five (5) days of filing with the Securities and Exchange Commission, copies of, or electronic links to (in the case of electronic links being provided to
Lenders, Borrower shall still be required to submit to Lenders the applicable compliance certificate in the form of Exhibit C), all statements, reports and notices made available to Borrower’s security holders or to any holders of
Subordinated Debt and all reports on Form 10-K, 10-Q and 8-K so filed. 
 (b) In addition, Borrower shall deliver to Lenders:
(i) a prompt report of any legal actions pending or threatened in writing against Borrower or any Subsidiary that would reasonably be expected to result in damages or costs to Borrower or any Subsidiary of One Hundred Thousand Dollars
($100,000.00) or more; and (ii) such other financial information as Lenders may reasonably request from time to time. 

(c) Within forty-five (45) days after the last day of each fiscal quarter, Borrower shall deliver to Lenders with the quarterly
financial statements a Compliance Certificate signed by a Responsible Officer in the form of Exhibit C. 
 (d) Borrower
shall allow Collateral Agent and Lenders to audit or inspect Borrower’s Collateral; provided that any such inspections shall be at Borrower’s expense and shall be conducted no more often than every twelve (12) months unless an Event
of Default has occurred and is continuing; provided further that any such audits shall only be conducted if an Event of Default has occurred and is continuing and shall be at Borrower’s expense. 

  
 8 

 6.3 Inventory; Returns. Borrower shall keep all Inventory in good and marketable
condition, free from material defects. Returns and allowances between Borrower and its account debtors shall follow Borrower’s customary practices as they exist at the Effective Date or as required by GAAP. Borrower must promptly notify Lenders
of all returns, recoveries, disputes and claims, which involve more than $150,000. 
 6.4 Taxes. Borrower shall make, and
cause each Subsidiary to make, timely payment of all material federal, state, and local taxes or assessments (other than taxes and assessments which Borrower is contesting in good faith, with adequate reserves maintained in accordance with GAAP) and
will deliver to Lenders, on demand, appropriate certificates attesting to such payments. 
 6.5 Insurance. Borrower shall
keep its business and the Collateral insured for risks in amounts, as reasonable and customary for a corporation with similar size and business as Borrower and as Lenders may reasonably request. Insurance policies shall be in a form, with companies,
and in amounts that are reasonably satisfactory to Lenders. All property policies covering Collateral shall have a lender’s loss payable endorsement showing each Lender as an additional loss payee and waive subrogation against Lenders, and all
liability policies shall show, or have endorsements showing, each Lender as an additional insured. All policies (or the loss payable and additional insured endorsements) shall provide that the insurer must give Lenders at least thirty (30) days
notice before canceling, amending, or declining to renew its policy. At Lenders’ request, Borrower shall deliver certified copies of policies and evidence of all premium payments. Proceeds payable under any policy shall, at Lenders’
option, be payable to Lenders on account of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to
$150,000, in the aggregate, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall
be deemed Collateral in which Lenders have been granted a first priority security interest, and (b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of
Lenders, be payable to Lenders on account of the Obligations. If Borrower fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons and Lenders, Lenders
may make all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Lenders deem prudent. 
 6.6 Accounts. 
 (a) Until all Obligations have been repaid, Borrower shall
maintain Borrower’s primary depository and operating accounts and securities accounts with SVB or administered through SVB, which accounts shall represent at least fifty percent (50%) of the dollar value of the Borrower’s accounts at
all financial institutions. 
 (b) Borrower shall identify to Lenders, in writing, any bank or securities account opened by
Borrower with any institution other than SVB. In addition, for each bank or securities account that the Borrower at any time opens or maintains, Borrower shall, prior to or in conjunction with the opening of such account, pursuant to an agreement in
form and substance acceptable to the Lenders cause such account to be subject to the “control” (within the meaning of 9-104 of the Code) of the Collateral Agent and cause the depository bank or securities intermediary to agree that such
account is the collateral of Collateral Agent acting for the Lenders pursuant to the terms hereunder. The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and
benefit payments to or for the benefit of the Borrower’s employees. 
 6.7 Intellectual Property. Borrower shall:
(a) use its commercially reasonable efforts to protect, defend and maintain the validity and enforceability of the Intellectual Property; (b) promptly advise Lenders in writing of material infringements of the Intellectual Property; and
(c) not allow any Intellectual Property material to the Borrower’s business to be abandoned, forfeited or dedicated to the public without Lenders’ written consent. 

6.8 Use of Proceeds. Borrower may use the proceeds of the Growth Capital Advances for general corporate purposes. 

6.9 Litigation Cooperation. From the date hereof and continuing through the termination of this Agreement, make available to
Collateral Agent and each Lender, without expense to Collateral Agent, Borrower’s officers, employees and agents and Borrower’s books and records, to the extent that Collateral Agent or any Lender may deem them reasonably necessary to
prosecute or defend any third-party suit or proceeding instituted by or against Collateral Agent or any Lender with respect to any Collateral or relating to Borrower. 

  
 9 

 6.10 Formation or Acquisition of Subsidiaries. At the time that Borrower forms any
direct or indirect Subsidiary or acquires any direct or indirect Subsidiary after the Effective Date, Borrower shall (a) cause such new Subsidiary to provide to Collateral Agent a joinder to the Loan Agreement to cause such Subsidiary to become
a co-borrower hereunder, together with such appropriate financing statements and/or Control Agreements, all in form and substance satisfactory to Collateral Agent (including being sufficient to grant Collateral Agent for the benefit of Lenders a
first priority Lien (subject to Permitted Liens) in and to the assets of such newly formed or acquired Subsidiary), (b) provide to Collateral Agent appropriate certificates and powers and financing statements, pledging all of the direct or
beneficial ownership interest in such new Subsidiary, in form and substance satisfactory to Collateral Agent, and (c) provide to Collateral Agent all other documentation in form and substance satisfactory to Collateral Agent which in its
opinion is appropriate with respect to the execution and delivery of the applicable documentation referred to above. Any document, agreement, or instrument executed or issued pursuant to this Section 6.10 shall be a Loan Document.

 6.11 Further Assurances. Borrower shall execute any further instruments and take further action as Collateral Agent or
Lenders reasonably request to perfect or continue Collateral Agent and Lenders’ security interest in the Collateral or to effect the purposes of this Agreement. 
  

	 	7.	NEGATIVE COVENANTS 

 Borrower shall
not do any of the following without the Lenders’ prior written consent for so long as any Lender has an obligation to make Credit Extensions or there are any outstanding Obligations: 

7.1 Dispositions. Convey, sell, lease, transfer or otherwise dispose of (collectively a “Transfer”), or permit
any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary course of business; (b) of worn-out or obsolete Equipment; (c) of non-exclusive licenses for the
use of the Intellectual Property of Borrower or its Subsidiaries; (d) exclusive licenses for the use of the Intellectual Property of Borrower or its Subsidiaries for a particular field of use or geographic area and approved by Borrower’s
Board of Directors; or (e) sales of securities in connection with Borrower’s cash management in the ordinary course of business, or (f) other Transfers in the ordinary course of business up to One Hundred Fifty Thousand Dollars
($150,000) per fiscal year. For the avoidance of doubt, the following shall not be considered a Transfer hereunder: payments of cash to vendors or other third parties for goods provided or to be provided or services rendered or to be rendered to or
on behalf of Borrower or any of its Subsidiaries in the ordinary course of business. Borrower shall not be permitted to make any Transfers to any Subsidiary that has not complied with the provisions of Section 6.10 without the
Lenders’ prior written consent. 
 7.2 Changes in Business, Ownership, Management or Locations of Collateral. Engage
in or permit any of its Subsidiaries to engage in any business other than the businesses currently engaged in by Borrower or reasonably related thereto, or liquidate or dissolve, or have a material change in its ownership (other than by the sale of
Borrower’s equity securities in a public offering or to venture capital investors so long as Borrower identifies to Lenders the venture capital investors prior to the closing of the investment), or a change in a Responsible Officer unless a
replacement is approved by a majority of Borrower’s Board of Directors, including a majority of those members of the Board of Directors who were members of the Board of Directors and not employees of Borrower (the “Outside
Directors”), within one hundred twenty (120) days of the date of termination of such Responsible Officer, provided that if a majority of the Outside Directors determine that such Responsible Officer shall not be replaced, then Borrower
shall notify Lenders within thirty (30) days of such determination. Borrower shall not, without at least thirty (30) days prior written notice to Lenders: (a) relocate its chief executive office, or add any new offices or business
locations, including warehouses (unless such new offices or business locations contain less than Five Thousand Dollars ($5,000) in Borrower’s assets or property), or (b) change its jurisdiction of organization, or (c) change its
organizational structure or type, or (d) change its legal name, or (e) change any organizational number (if any) assigned by its jurisdiction of organization. 
 7.3 Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or
substantially all of the capital stock or property of another Person; provided, however, if Lenders do not consent to any such transaction, then Borrower shall be entitled to prepay all of the Obligations without payment of the Prepayment Fee (as
more fully set forth in Section 2.2(e) of this Agreement) if such prepayment occurs contemporaneously with such proposed merger or acquisition. Notwithstanding the foregoing, (a) a Subsidiary may merge or consolidate into another
Subsidiary or into Borrower (so long as the Borrower is the surviving entity), and (b) Borrower may merge or consolidate so long as: (i) the entity that results from such merger or consolidation (the “Surviving Entity”)
shall have executed and delivered to Lenders 

  
 10 

 
an agreement in form and substance reasonably satisfactory to Lenders, containing an assumption by the Surviving Entity of the due and punctual payment and performance of all Obligations and
performance and observance of each covenant and condition of Borrower in the Loan Documents; (ii) all such obligations of the Surviving Entity to Lenders shall be guaranteed by any entity, if any, that directly or indirectly owns or controls
more than fifty percent (50%) of the voting stock of the Surviving Entity; (iii) before and immediately after giving effect to such merger or consolidation, no default or Event of Default shall have occurred and be continuing; and
(iv) the credit risk to any Lender, in its sole discretion, of the Surviving Entity shall not be increased. In determining whether the proposed merger or consolidation would result in an increased credit risk, each Lender may consider, among
other things, changes in Borrower’s management team, employee base, access to equity markets, venture capital support, financial position and/or disposition of intellectual property rights which may reasonably be anticipated as a result of the
transaction. 
 7.4 Indebtedness. Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to
do so, other than Permitted Indebtedness. 
 7.5 Encumbrance. Create, incur, or allow any Lien on any of the Collateral,
or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not to be subject to the first priority security interest granted
herein, except for Permitted Liens as to which the Collateral may be subject. Borrower shall not sell, transfer, assign, mortgage, pledge, lease, grant a security interest in, or encumber, or enter into any agreement, document, instrument or other
arrangement (except with or in favor of Collateral Agent) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower from selling, transferring, assigning, mortgaging, pledging, leasing, granting a security
interest in or upon, or encumbering any of Borrower’s Intellectual Property, except for Transfers permitted pursuant to the terms and conditions of Section 7.1. 

7.6 Distributions; Investments. 
 (a) Directly or indirectly acquire or own any Person, or make any Investment in any Person, other than Permitted Investments or mergers or acquisitions permitted by Section 7.3 above, or
permit any of its Subsidiaries to do so; or (b) pay any dividends or make any distribution or payment or redeem, retire or purchase any capital stock except (i) dividends and distributions payable solely in capital stock of Borrower and
(ii) repurchases of stock from former employees, consultants or directors of Borrower under the terms of applicable repurchase agreements in an aggregate amount not to exceed Fifty Thousand Dollars ($50,000) in the aggregate in any fiscal year
provided that no Event of Default has occurred, is continuing or would exist after giving effect to any such repurchase. 

7.7 Transactions with Affiliates. Directly or indirectly enter into or permit to exist any material transaction with any Affiliate
of Borrower except for (a) transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an arm’s length transaction with a
non-affiliated Person, (b) Borrower’s sale of equity securities to venture capital investors, or (c) compensation and benefit arrangements (including the granting of options or other equity compensation arrangements) and any
indemnification arrangements with employees, officers, directors or consultants approved by or pursuant to any plan approved by the majority of the disinterested members of the board of directors of Borrower. 

7.8 Subordinated Debt. 
 (a) Make or permit any payment on any Subordinated Debt, except under the terms of the Subordinated Debt, or (b) amend any provision in any document relating to the Subordinated Debt that would
breach any applicable subordination agreement entered into in favor of Collateral Agent or Lenders or that would reasonably be expected to cause a Material Adverse Change. 
 7.9 Compliance. Become an “investment company” or a company controlled by an “investment company,” under the Investment Company Act of 1940 or undertake as one of its important
activities extending credit to purchase or carry margin stock, or use the proceeds of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in
ERISA, to occur; fail to comply with the Federal Fair Labor Standards Act or violate any other law or regulation, if the violation would reasonably be expected to cause a Material Adverse Change, or permit any of its Subsidiaries to do so.

  
 11 

 7.10 Indebtedness Payments. 

(a) Prepay, redeem, purchase, defease or otherwise satisfy in any manner prior to the scheduled repayment thereof any Indebtedness for
borrowed money (other than amounts due under this Agreement or due any Lender) or lease obligations, (b) amend, modify or otherwise change the terms of any Indebtedness for borrowed money or lease obligations so as to accelerate the scheduled
repayment thereof or (c) repay any notes to officers, directors or shareholders. 
  

	 	8.	EVENTS OF DEFAULT 

 Any one of the following is an Event of Default: 
 8.1 Payment Default.
Borrower fails to pay any of the Obligations within three (3) Business Days after their due date. During the additional three (3) Business Day period the failure to cure the default shall not constitute an Event of Default (but no Credit
Extension shall be made during such cure period). 
 8.2 Covenant Default. 

(a) If Borrower fails to perform any obligation under Sections 6.2, 6.6 or 6.7 or violates any of the covenants contained
in Section 7 of this Agreement, or 
 (b) If Borrower fails or neglects to perform, keep, or observe any other
material term, provision, condition, covenant, or agreement contained in this Agreement (other than as described in Section 8.2(a)), in any of the Loan Documents, or in any other present or future agreement between Borrower and any
Lender and as to any default under such other term, provision, condition, covenant or agreement that can be cured, has failed to cure such default within ten (10) days after the occurrence thereof; provided, however, that if the default cannot
by its nature be cured within the ten (10) day period or cannot after diligent attempts by Borrower be cured within such ten (10) day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an
additional reasonable period (which shall not in any case exceed thirty (30) days after the end of such ten (10) day period) to attempt to cure such default, and within such reasonable time period the failure to have cured such default
shall not be deemed an Event of Default (provided that no Credit Extensions will be made during such cure period). 
 8.3
Material Adverse Change. A Material Adverse Change occurs. 
 8.4 Attachment. 

(a) Any material portion of Borrower’s assets is attached, seized, levied on, or comes into possession of a trustee or receiver and
the attachment, seizure or levy is not removed in ten (10) days; (b) the service of process upon the Borrower seeking to attach, by trustee or similar process, any funds of the Borrower on deposit with the Lenders and/or Collateral Agent,
or any entity under the control of Lenders and/or Collateral Agent (including a subsidiary) and the service of process is not rescinded or withdrawn within ten (10) days; (c) Borrower is enjoined, restrained, or prevented by court order
from conducting a material part of its business; (d) a judgment or other claim becomes a Lien on a material portion of Borrower’s assets; or (e) a notice of lien, levy, or assessment is filed against any of Borrower’s assets by
any government agency and not paid within ten (10) days after Borrower receives notice. These are not Events of Default if stayed or if a bond is posted pending contest by Borrower (but no Credit Extensions shall be made during the cure
period). 
 8.5 Insolvency. 
 (a) Borrower is unable to pay its debts (including trade debts) as they mature; (b) Borrower begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower and not
dismissed or stayed within forty-five (45) days (but no Credit Extensions shall be made before any Insolvency Proceeding is dismissed). 
 8.6 Other Agreements. If there is a default in any agreement to which Borrower is a party with a third party or parties resulting in a right by such third party or parties, whether or not
exercised, to accelerate the maturity of any Indebtedness in an amount in excess of One Hundred Thousand Dollars ($100,000) or that could otherwise result in a Material Adverse Change or if any subordination agreement is unenforceable. 

8.7 Judgments. If a judgment or judgments for the payment of money in an amount, individually or in the aggregate, of at least Two
Hundred Fifty Thousand Dollars ($250,000) shall be rendered against Borrower and shall 

  
 12 

 
remain unsatisfied and unstayed for a period of ten (10) days (provided that no Credit Extensions will be made prior to the satisfaction or stay of such judgment). 

8.8 Misrepresentations. If Borrower or any authorized Person acting for Borrower makes any material misrepresentation or material
misstatement now or later in any warranty or representation in this Agreement or in any writing delivered to Collateral Agent or Lenders or to induce Collateral Agent or Lenders to enter this Agreement or any Loan Document. 

8.9 Guaranty. 
 (a) Any guaranty of any Obligations terminates or ceases for any reason to be in full force; or (b) any Guarantor does not perform any obligation under any guaranty of the Obligations; or
(c) any material misrepresentation or material misstatement exists now or later in any warranty or representation in any guaranty of the Obligations or in any certificate delivered to Lenders in connection with the guaranty; or (d) any
circumstance described in Sections 8.3, 8.4, 8.5, or 8.8 occurs to any Guarantor, or (e) the liquidation, winding up, termination of existence, or insolvency of any Guarantor. 

 

	 	9.	RIGHTS AND REMEDIES 

9.1 Rights and Remedies. When an Event of Default occurs and continues Collateral Agent may, without notice or demand, do any or
all of the following: 
 (a) Declare all Obligations immediately due and payable (but if an Event of Default described in
Section 8.5 occurs all Obligations are immediately due and payable without any action by Collateral Agent); 
 (b)
Stop advancing money or extending credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and any Lender; 
 (c) Settle or adjust disputes and claims directly with account debtors for amounts, on terms and in any order that Lenders consider advisable and notify any Person owing Borrower money of Lenders’
security interest in such funds and verify the amount of such account. Borrower shall collect all payments in trust for Lenders and, if requested by Lenders, immediately deliver the payments to Lenders in the form received from the account debtor,
with proper endorsements for deposit; 
 (d) Make any payments and do any acts it considers necessary or reasonable to protect
their security interest in the Collateral. Borrower shall assemble the Collateral if Collateral Agent requests and make it available as Collateral Agent designates. Collateral Agent may enter premises where the Collateral is located, take and
maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Collateral Agent a license to enter
and occupy any of its premises, without charge, to exercise any of Collateral Agent’s rights or remedies; 
 (e) Apply to
the Obligations any (i) balances and deposits of Borrower it holds, or (ii) any amount held by any Lender owing to or for the credit or the account of Borrower; 
 (f) Ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral. Collateral Agent is hereby granted a non-exclusive, royalty-free license or
other right to use, without charge, Borrower’s labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar property as it pertains to the
Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Collateral Agent’s exercise of its rights under this Section, Borrower’s rights under all licenses and all franchise
agreements inure to Collateral Agent for the benefit of Lenders; 
 (g) Place a “hold” on any account maintained with
any Lender (provided that, except with respect to any certificates of deposit or deposit or investment accounts pledged as Collateral to secure cash management services, corporate business credit cards or letters of credit separately issued or
supplied by SVB under separate agreements between SVB and Borrower, Collateral Agent and Lenders agree not to take any of the actions described in this clause (g) unless an Event of Default has occurred and is continuing); 

  
 13 

 (h) Deliver a notice of exclusive control, any entitlement order, or other directions or
instructions pursuant to any control agreement or similar agreements providing control of any Collateral (provided that, Collateral Agent and Lenders agree not to take any of the actions described in this clause (h) unless an Event of Default
has occurred and is continuing); 
 (i) Demand and receive possession of Borrower’s Books; and 

(j) Exercise all rights and remedies and dispose of the Collateral according to the Code. 

9.2 Power of Attorney. Borrower hereby irrevocably appoints Collateral Agent and each Lender as its lawful attorney-in-fact, to be
effective upon the occurrence and during the continuance of an Event of Default, to: (a) endorse Borrower’s name on any checks or other forms of payment or security; (b) sign Borrower’s name on any invoice or bill of lading for
any Account or drafts against account debtors, (c) settle and adjust disputes and claims about the Accounts directly with account debtors, for amounts and on terms Collateral Agent or such Lender determines reasonable; (d) make, settle,
and adjust all claims under Borrower’s insurance policies; and (e) transfer the Collateral into the name of Collateral Agent or such Lender or a third party as the Code permits. Borrower hereby appoints Collateral Agent and each Lender as
its lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue the perfection of any security interest regardless of whether an Event of Default has occurred until all Obligations have been satisfied in
full and Lenders are under no further obligation to make Credit Extensions hereunder. Collateral Agent and each Lender’s foregoing appointment as Borrower’s attorney in fact, and all of Collateral Agent’s and such Lender’s rights
and powers, coupled with an interest, are irrevocable until all Obligations have been fully repaid and performed and Lenders’ obligation to provide Credit Extensions terminates. 

9.3 Accounts, Notification and Collection. In the event that an Event of Default occurs and is continuing, Collateral Agent or
Lenders may notify any Person owing Borrower money of Collateral Agent’s and Lenders’ security interest in the funds and verify and/or collect the amount of the Account. After the occurrence of an Event of Default, any amounts received by
Borrower shall be held in trust by Borrower for Lenders, and, if requested by Lenders, Borrower shall immediately deliver such receipts to Lenders in the form received from the account debtor, with proper endorsements for deposit. 

9.4 Lenders Expenses. Any amounts paid by Lenders as provided herein are Lenders Expenses and are immediately due and payable and
shall bear interest at the then applicable rate and be secured by the Collateral. No payments by Lenders shall be deemed an agreement to make similar payments in the future or Lenders’ waiver of any Event of Default. 

9.5 Lenders’ Liability for Collateral. So long as Collateral agent and Lenders comply with their obligations, if any, under
the Code, Collateral Agent and no Lender shall in any way or manner be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or
(d) any act or default of any carrier, warehouseman, bailee, or other Person. Borrower bears all risk of loss, damage or destruction of the Collateral. 
 9.6 Remedies Cumulative. Collateral Agent’s and Lenders’ rights and remedies under this Agreement, the Loan Documents, and all other agreements are cumulative. Collateral Agent and
Lenders have all rights and remedies provided under the Code, by law, or in equity. Collateral Agent or Lenders’ exercise of one right or remedy is not an election, and Lenders’ waiver of any Event of Default is not a continuing waiver.
Collateral Agent’s or Lenders’ delay is not a waiver, election, or acquiescence. No waiver hereunder shall be effective unless signed by Collateral Agent and each Lender and then is only effective for the specific instance and purpose for
which it was given. 
 9.7 Demand Waiver. Borrower waives demand, notice of default or dishonor, notice of payment and
nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Lenders on which Borrower is liable. In all cases,
Lenders’ recourse under this Agreement is limited to the amount of the Obligations and any other payments for which Borrower is responsible hereunder. 

  
 14 

	 	10.	NOTICES 

 Notices
or demands by any party about this Agreement must be in writing and personally delivered or sent by an overnight delivery service, or by certified mail, postage prepaid, return receipt requested, or by telefacsimile at the addresses listed below. A
party may change its notice address by written notice to the other party. 
  

					
	 	  	If to Borrower:	  	Cadence Pharmaceuticals, Inc.
		  		  	12481 High Bluff Drive, Suite 200
		  		  	San Diego, CA 92130
		  		  	Attn: General Counsel
		  		  	Fax: (858) 436-8510
			
		  		  	With a copy to:
			
		  		  	Latham & Watkins LLP
		  		  	12636 High Bluff Drive, Suite 400
		  		  	San Diego, CA 92130
		  		  	Attn: Cheston Larson
		  		  	Fax: (858) 523-5450
			
		  	If to SVB:	  	Silicon Valley Bank
		  		  	555 Mission Street, 9th Floor
		  		  	San Francisco, CA 94105
		  		  	Attn: Michael White
		  		  	Fax: (415) 856-0810
			
		  	If to Oxford:	  	Oxford Finance LLC
		  		  	133 North Fairfax Street
		  		  	Alexandria, VA 22314
		  		  	 Attn: Tim Lex, Chief Operating Officer and Executive Vice
 President

		  		  	Facsimile: (703) 519-6010
			
		  		  	With a copy to:
			
		  		  	Oxford Finance LLC
		  		  	133 North Fairfax Street
		  		  	Alexandria, VA 22314
		  		  	Attn: John Henderson, Vice President and General Counsel
		  		  	Facsimile: (703) 519-6010
			
		  	If to GECC:	  	General Electric Capital Corporation
		  		  	c/o GE Healthcare Financial Services, Inc.
		  		  	Two Bethesda Metro Center, Suite 600
		  		  	Bethesda, Maryland 20814
		  		  	Attention: Senior Vice President of Risk – Life Science Finance
		  		  	Facsimile: (301) 664-98558
			
		  		  	With a copy to:
			
		  		  	General Electric Capital Corporation
		  		  	c/o GE Healthcare Financial Services, Inc.
		  		  	Two Bethesda Metro Center, Suite 600
		  		  	Bethesda, Maryland 20814
		  		  	Attention: General Counsel
		  		  	Facsimile: (301) 664-9866

  

	 	11.	CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER 

 California law governs the Loan Documents without regard to principles of conflicts of law. Borrower, Collateral Agent and Lenders each submit to the exclusive jurisdiction of the State and Federal courts
in California and 

  
 15 

 
Borrower accepts jurisdiction of the courts and venue in Santa Clara County, California. NOTWITHSTANDING THE FOREGOING, COLLATERAL AGENT AND THE LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION
OR PROCEEDING AGAINST THE BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH THE LENDERS DEEM NECESSARY OR APPROPRIATE IN ORDER TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE THE LENDERS’ RIGHTS AGAINST THE BORROWER OR
ITS PROPERTY. 
 TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, COLLATERAL AGENT AND EACH LENDER WAIVE THEIR
RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL
INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL. 
 WITHOUT
INTENDING IN ANY WAY TO LIMIT THE PARTIES’ AGREEMENT TO WAIVE THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY, if the above waiver of the right to a trial by jury is not enforceable, the parties hereto agree that any and all disputes or controversies
of any nature between them arising at any time shall be decided by a reference to a private judge, mutually selected by the parties (or, if they cannot agree, by the Presiding Judge of the Santa Clara County, California Superior Court) appointed in
accordance with California Code of Civil Procedure Section 638 (or pursuant to comparable provisions of federal law if the dispute falls within the exclusive jurisdiction of the federal courts), sitting without a jury, in Santa Clara County,
California; and the parties hereby submit to the jurisdiction of such court. The reference proceedings shall be conducted pursuant to and in accordance with the provisions of California Code of Civil Procedure §§ 638 through 645.1,
inclusive. The private judge shall have the power, among others, to grant provisional relief, including without limitation, entering temporary restraining orders, issuing preliminary and permanent injunctions and appointing receivers. All such
proceedings shall be closed to the public and confidential and all records relating thereto shall be permanently sealed. If during the course of any dispute, a party desires to seek provisional relief, but a judge has not been appointed at that
point pursuant to the judicial reference procedures, then such party may apply to the Santa Clara County, California Superior Court for such relief. The proceeding before the private judge shall be conducted in the same manner as it would be before
a court under the rules of evidence applicable to judicial proceedings. The parties shall be entitled to discovery which shall be conducted in the same manner as it would be before a court under the rules of discovery applicable to judicial
proceedings. The private judge shall oversee discovery and may enforce all discovery rules and orders applicable to judicial proceedings in the same manner as a trial court judge. The parties agree that the selected or appointed private judge shall
have the power to decide all issues in the action or proceeding, whether of fact or of law, and shall report a statement of decision thereon pursuant to the California Code of Civil Procedure § 644(a). Nothing in this paragraph shall limit the
right of any party at any time to exercise self-help remedies, foreclose against collateral, or obtain provisional remedies. The private judge shall also determine all issues relating to the applicability, interpretation, and enforceability of this
paragraph. 
  

	 	12.	GENERAL PROVISIONS 

12.1 Successors and Assigns. This Agreement binds and is for the benefit of the successors and permitted assigns of each party.
Borrower may not transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent’s and each Lender’s prior written consent (which may be granted or withheld in Collateral Agent’s and each
Lender’s discretion, subject to Section 12.6). The Lenders have the right, without the consent of or notice to Borrower, to sell, transfer, assign, pledge, negotiate, or grant participation in (any such sale, transfer, assignment,
negotiation, or grant of a participation, a “Lender Transfer”) all or any part of, or any interest in, the Lenders’ obligations, rights, and benefits under this Agreement and the other Loan Documents; provided, however, that
any such Lender Transfer (other than a transfer, pledge, sale or assignment to an Eligible Assignee) of its obligations, rights, and benefits under this Agreement and the other Loan Documents shall require the prior written consent of the Required
Lenders (such approved assignee, an “Approved Lender”). Borrower and Collateral Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned until Collateral Agent
shall have received and accepted an effective assignment agreement in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such
Eligible Assignee or Approved Lender as Collateral Agent reasonably shall require. Notwithstanding anything to the contrary contained herein, so long as no Event of Default has occurred and is continuing, no Lender Transfer (other than a Lender
Transfer (a) in respect of the Warrants or (b) in connection with (i) assignments by a Lender due to a forced divestiture at the request of any regulatory agency; or (ii) a Lender’s own financing or securitization
transactions and upon the occurrence of a default, Event of Default or similar occurrence with respect to such financing or 

  
 16 

 
securitization transaction) shall be permitted to any Person if such person is an Affiliate or Subsidiary of Borrower, a direct competitor of Borrower or a vulture hedge fund, each as determined
by Collateral Agent, without Borrower’s consent. 
 12.2 Indemnification. Borrower hereby indemnifies, defends and
holds Collateral Agent and Lenders and their respective officers, employees, and agents harmless against: (a) all obligations, demands, claims, and liabilities asserted by any other party in connection with the transactions contemplated by the
Loan Documents; and (b) all losses or Lenders Expenses incurred, or paid by Lenders from, following, or consequential to transactions between Lenders and Borrower (including reasonable attorneys’ fees and expenses), except, as to
(a) and (b), for losses caused by Collateral Agent’s or a Lender’s gross negligence or willful misconduct, as applicable. 
 12.3 Attorneys’ Fees, Costs and Expenses. In any action or proceeding between Borrower and Collateral Agent or any Lender arising out of the Loan Documents the prevailing party will be
entitled to recover its reasonable attorneys’ fees and other reasonable costs and expenses incurred, in addition to any other relief to which it may be entitled. 
 12.4 Right of Set-Off. Borrower hereby grants to each Lender, a lien, security interest and right of set-off as security for all Obligations to such Lender, hereunder, whether now existing or
hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of such Lender or any entity under the control of such Lender (including a subsidiary of Lender)
or in transit to any of them. At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, a Lender may set-off the same or any part thereof and apply the same to any liability or obligation of
Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE ANY LENDER TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE
OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF THE BORROWER, ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED. 

12.5 Time of Essence. Time is of the essence for the performance of all Obligations in this Agreement. 

12.6 Severability of Provision. Each provision of this Agreement is severable from every other provision in determining the
enforceability of any provision. 
 12.7 Amendments in Writing, Integration. All amendments to this Agreement must be in
writing and signed by all Lenders and Borrower. This Agreement and the Loan Documents represent the entire agreement about this subject matter, and supersede prior negotiations or agreements. All prior agreements, understandings, representations,
warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents. 
 12.8 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, are an original, and
all taken together, constitute one Agreement. Any facsimile or .pdf file bearing a physical signature shall be treated and considered an original for purposes of the effectiveness of the Loan Documents. 

12.9 Survival. All covenants, representations and warranties made in this Agreement continue in full force while any Obligations
remain outstanding. Without limiting the foregoing, the grant of security interest by Borrower in Section 4.1 shall survive until the earlier of (a) Borrower providing cash collateral in accordance with Section 4.1 or
(b) the termination of all Bank Services Agreements. The obligations of Borrower to indemnify any Lender, including without limitation Section 12.2, shall survive until the statute of limitations with respect to such claim or cause
of action shall have run. This Agreement and the grant of the security interest in the Collateral hereunder shall automatically be reinstated if any Lender is ever required to return or restore the payment of all or any portion of the Obligations
(all as though such payment had never been made). 
 12.10 Confidentiality. In handling any confidential information of
Borrower or Borrower’s Affiliates, each Lender shall exercise the same degree of care that it exercises for its own proprietary information, but disclosure of information may be made: (a) to a Lender’s subsidiaries or affiliates in
connection with their business with Borrower; (b) to prospective transferees or purchasers of any interest in the Credit Extensions (provided, however, such Lender shall use commercially reasonable efforts in obtaining such prospective
transferee’s or purchaser’s agreement to the terms of 

  
 17 

 
this provision); (c) as required by law, regulation, subpoena, or other order, (d) as required in connection with a Lender’s examination or audit; and (e) as Lenders consider
appropriate in exercising remedies under this Agreement. Confidential information does not include information that either: (i) is in the public domain or in a Lender’s possession when disclosed to Lenders, or becomes part of the public
domain after disclosure to Lenders through no fault of Lenders; or (ii) is disclosed to a Lender by a third party, if Lenders do not know that the third party is prohibited from disclosing the information. 

12.11 Effective Date. Notwithstanding anything set forth in this Agreement or any Loan Document to the contrary, this Agreement
and all of the Loan Documents shall not be effective until the date on which Collateral Agent and each Lender executes this Agreement as indicated on the signature page to this Agreement. 

12.12 Effect of Amendment and Restatement. This Agreement is intended to and does completely amend and restate, without novation,
the Original Agreement. All security interests granted under the Original Agreement are hereby confirmed and ratified as of the date first granted and filed and shall continue to secure all Obligations under this Agreement. 

 

	 	13.	DEFINITIONS 

13.1 Definitions. In this Agreement: 
 “Accounts” are all existing and later arising accounts, contract rights, and other obligations owed Borrower in connection with its sale or lease of goods (including licensing software
and other technology) or provision of services, all credit insurance, guaranties, other security and all merchandise returned or reclaimed by Borrower and Borrower’s Books relating to any of the foregoing, as such definition may be amended from
time to time according to the Code. 
 “Additional Growth Capital Advance” is defined in
Section 2.1.1(a). 
 “Additional Growth Capital Amount” is defined in Section 2.1.1(a).

 “Additional Growth Capital Funding Date” is the date on which the Additional Growth Capital Advance is made
to or on account of Borrower. 
 “Affiliate” is a Person that owns or controls directly or indirectly the
Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and, for any Person that is a limited liability company, that
Person’s managers and members. 
 “Agreement” is defined in the Preamble hereto. 

“American Express Facility” means a corporate credit card facility provided to Borrower by American Express not to
exceed Four Hundred Fifty Thousand Dollars ($450,000) in the aggregate principal amount outstanding at any time. 

“Approved Fund” means any (i) investment company, fund, trust, securitization vehicle or conduit that is (or will
be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business or (ii) any Person (other than a natural person) which temporarily warehouses loans
for any Lender or any entity described in the preceding clause (i) and that, with respect to each of the preceding clauses (i) and (ii), is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) a
Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender. 
 “Approved Lender” has the meaning given it in Section 12.1. 
 “Bank Services” are any products, credit services, and/or financial accommodations previously, now, or hereafter provided to Borrower or any of its Subsidiaries by SVB or any SVB
Affiliate, including, without limitation, any letters of credit, cash management services (including, without limitation, merchant services, direct deposit of payroll, business credit cards, and check cashing services), interest rate swap
arrangements, and foreign exchange services as any such products or services may be identified in SVB’s various agreements related thereto (each, a “Bank Services Agreement”); provided that the aggregate amount of such Bank
Services shall not exceed (i) Three Hundred 

  
 18 

 
Thousand Dollars ($300,000) plus (ii) to the extent greater than zero, Four Hundred Fifty Thousand Dollars ($450,000) less the amount of the American Express Facility. 

“Bank Services Agreement” is defined in the definition of Bank Services. 

“Basic Rate” is defined in Section 2.2(b)(i). 

“Borrower” is defined in the Preamble hereto. 
 “Borrower’s Books” are all Borrower’s books and records including ledgers, records regarding Borrower’s assets or liabilities, the Collateral, business operations or
financial condition and all computer programs or discs or any equipment containing the information. 
 “Business
Day” is any day that is not a Saturday, Sunday or a day on which SVB is closed. 
 “Code” is the
Uniform Commercial Code as adopted in California as amended and in effect from time to time. 
 “Collateral” is
any and all properties, rights and assets of the Borrower granted by the Borrower to Lenders or arising under the Code, now, or in the future, described on Exhibit A. 
 “Collateral Agent” is defined in the Preamble hereto 

“Contingent Obligation” is, for any Person, any direct or indirect liability, contingent or not, of that Person for
(i) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is
directly or indirectly liable; (ii) any obligations for undrawn letters of credit for the account of that Person; and (iii) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar
agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent Obligation” does not include endorsements in the ordinary
course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it
determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under the guarantee or other support arrangement. 
 “Copyrights” are all copyright rights, applications or registrations and like protections in each work or authorship or derivative work, whether published or not (whether or not it is a
trade secret) now or later existing, created, acquired or held. 
 “Credit Extension” is the Growth Capital
Advances or any other extension of credit by any Lender for Borrower’s benefit made pursuant to this Agreement. 

“Default Rate” means for each Growth Capital Advance, five percent (5%) above the highest rate otherwise applicable
thereto. 
 “Disbursement Letter” is that certain form attached hereto as Exhibit B-1. 

“Dollars” and “$” each means the lawful currency of the United States. 

“Dollar Equivalent” is, at any time, (a) with respect to any amount denominated in Dollars, such amount, and
(b) with respect to any amount denominated in a Foreign Currency, the equivalent amount therefor in Dollars as determined by SVB at such time on the basis of the then-prevailing rate of exchange in San Francisco, California, for sales of the
Foreign Currency for transfer to the country issuing such Foreign Currency. 
 “Effective Date” is the date
Collateral Agent and Lenders execute this Agreement and as indicated on the signature page hereof. 
 “Eligible
Assignee” means (i) a Lender, (ii) an Affiliate of a Lender, (iii) an Approved Fund and (iv) any commercial bank, savings and loan association or savings bank or any other entity which is an “accredited
investor” (as 

  
 19 

 
defined in Regulation D under the Securities Act of 1933, as amended) and which extends credit or buys loans as one of its businesses, including insurance companies, mutual funds, lease financing
companies and commercial finance companies, in each case, which either (A) has a rating of BBB or higher from Standard & Poor’s Rating Group and a rating of Baa2 or higher from Moody’s Investors Service, Inc. at the date that
it becomes a Lender or (B) has total assets in excess of Five Billion Dollars ($5,000,000,000), and in each case of clauses (i) through (iv), which, through its applicable lending office, is capable of lending to Borrower without the
imposition of any withholding or similar taxes; provided that notwithstanding the foregoing, “Eligible Assignee” shall not include, unless an Event of Default has occurred and is continuing, (i) Borrower or any of Borrower’s
Affiliates or Subsidiaries or (ii) a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent. Notwithstanding the foregoing, (x) in connection with assignments by a Lender due to a forced divestiture
at the request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party and (y) in connection with a Lender’s own financing or securitization transactions, the
restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a
default, event of default or similar occurrence with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations
hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Collateral Agent executed,
delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Collateral Agent reasonably shall require. 

“Equipment” is all present and future machinery, equipment, tenant improvements, furniture, fixtures, vehicles, tools,
parts and attachments in which Borrower has any interest. 
 “ERISA” is the Employment Retirement Income
Security Act of 1974, and its regulations. 
 “Exchange Act” is defined in Section 6.2. 

“Existing Final Payment” is defined in Section 2.4(c). 

“Existing Growth Capital Advances” is defined in Section 2.1.2. 

“Existing Notes” is defined in Section 2.3. 

“Foreign Currency” means lawful money of a country other than the United States. 

“FDA” is defined in Section 6.1. 
 “GAAP” is generally accepted accounting principles. 

“GECC” is defined in the Preamble hereto. 
 “GECC Warrant” is that certain Warrant to Purchase Stock dated as of the Effective Date executed by Borrower in favor of GECC’s Affiliate, GE Capital Equity Investment, Inc.

 “Governmental Authority” is any nation or government, any state or other political subdivision thereof, any
agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any
self-regulatory organization. 
 “Growth Capital Advances” means, collectively, the Existing Growth Capital
Advances and the Additional Growth Capital Advance, and “Growth Capital Advance” means each of the foregoing individually. 
 “Growth Capital Amortization Date” means January 1, 2013. 

“Growth Capital Commitment Percentage” means fifty percent (50%) with respect to Oxford, thirty-one and two thirds
percent (31.67%) with respect to GECC and eighteen and one third percent (18.33%) with respect to SVB. 

  
 20 

 “Growth Capital Final Payment” means a payment (in addition to and not a
substitution for the regular monthly payments of principal plus accrued interest) due on the earlier of (i) the Growth Capital Maturity Date, (ii) any prepayment of the Growth Capital Advances, or (iii) the acceleration of the Growth
Capital Advances, equal to the Growth Capital Advances multiplied by the Growth Capital Final Payment Percentage. 

“Growth Capital Final Payment Percentage” is six percent (6%). 

“Growth Capital Loan Commitment” is in respect of the Existing Growth Capital Advances and the Additional Growth Capital
Advance, collectively, Thirty Million Dollars ($30,000,000). 
 “Growth Capital Interest Only Period” means the
period of time commencing on the Additional Growth Capital Funding Date and continuing through and including December 31, 2012. 
 “Growth Capital Maturity Date” is the earliest of (i) June 1, 2015, or (ii) the occurrence of an Event of Default and acceleration of the Obligations as a consequence
thereof. 
 “Growth Capital Repayment Period” is a period of time equal to twenty-nine (29) consecutive
months commencing on the Growth Capital Amortization Date. 
 “Guarantor” is any present or future guarantor of
the Obligations. 
 “Indebtedness” is (i) indebtedness for borrowed money or the deferred price of
property or services, such as reimbursement and other obligations for surety bonds and letters of credit, (ii) obligations evidenced by notes, bonds, debentures or similar instruments, (iii) capital lease obligations and
(iv) Contingent Obligations. 
 “Insolvency Proceeding” is any proceeding by or against any Person under
the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other
relief. 
 “Intellectual Property” is: 
 (a) Copyrights, Trademarks, Patents, Know-How and Mask Works including amendments, renewals, extensions; 
 (b) All licenses or other rights to use and all license fees and royalties from the use of the intellectual property rights in (a) above and (c) and (d) below; 

(c) Any trade secrets and any intellectual property rights in methods, processes, technologies, computer software and computer software
products now or later existing, created, acquired or held; 
 (d) All design rights which may be available to Borrower now or
later created, acquired or held; 
 (e) Any claims for damages (past, present or future) for infringement of any of the rights
above, with the right, but not the obligation, to sue and collect damages for use or infringement of the intellectual property rights in (a), (b), (c) and (d) above; 
 (f) All Proceeds and products of the foregoing, including all insurance, indemnity or warranty payments, 
 In the case of each of (a), (b), (c) and (d) to the extent such intellectual property rights are (A) owned by or exclusively licensed to Borrower (or any Subsidiary) or (B) material to
the operation of Borrower’s business (taken as a whole) as then conducted. 
 “Inventory” is present and
future inventory in which Borrower has any interest, including merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products intended for sale or lease or to be furnished under a contract of
service, of every kind and description now or later owned by or in the custody or possession, actual or constructive, of Borrower, including inventory temporarily out of its custody or possession or in transit and including returns on any accounts
or other proceeds (including insurance proceeds) from the sale or disposition of any of the foregoing and any documents of title. 

  
 21 

 “Investment” is any beneficial ownership of (including stock, partnership
interest or other securities) any Person, or any loan, advance or capital contribution to any Person. 

“Know-How” means all ideas, inventions, scientific information, procedures, instructions, techniques, designs, formulas,
methods, data, technical information (including toxicological, pharmaceutical, non-clinical, clinical and medical data, health registration data and marketing data), processing specifications, pricing studies and market evaluation materials and all
intellectual property rights therein owned, licensed or sublicensed by Borrower. 
 “Lenders Expenses” are all
audit fees and expenses and reasonable costs or expenses (including reasonable attorneys’ fees and expenses) for preparing, negotiating, administering, defending and enforcing the Loan Documents (including appeals or Insolvency Proceedings).

 “Lender Transfer” has the meaning given it in Section 12.1. 

“Letter of Credit” is a standby or commercial letter of credit issued by SVB upon request of Borrower based upon an
application, guarantee, indemnity or similar agreement. 
 “Letter-of-Credit Right” means a right to payment or
performance under a letter of credit, whether or not the beneficiary has demanded or is at the time entitled to demand payment or performance. 
 “Lien” is a mortgage, lien, deed of trust, charge, pledge, security interest or other encumbrance. 
 “Loan Documents” are, collectively, this Agreement, the Perfection Certificate, each Compliance Certificate, any Bank Services Agreement, any subordination agreement, any note, or notes
or guaranties executed by Borrower and any other present or future agreement between Borrower and/or Guarantor for the benefit of Lenders or Collateral Agent in connection with this Agreement, all as amended, extended, restated or otherwise
modified. 
 “Loan Payment/Advance Request Form” is that certain form attached hereto as Exhibit B-2.

 “Mask Works” are all mask works or similar rights available for the protection of semiconductor chips, now
owned or later acquired. 
 “Material Adverse Change” is: (i) a material impairment in the perfection or
priority of Collateral Agent’s or Lenders’ security interest in the Collateral; or (ii) a material impairment of the prospect of repayment of any portion of the Obligations. 

“Obligations” are debts, principal, interest, Prepayment Fee, Growth Capital Final Payment, the Existing Final Payment,
Lenders’ Expenses, and other amounts Borrower owes any Lender now or later under or in connection with this Agreement, including cash management services, letters of credit and foreign exchange contracts, if any and including interest accruing
after Insolvency Proceedings begin and debts, liabilities, or obligations of Borrower assigned to Lenders. 
 “Operating
Documents” are, for any Person, such Person’s formation documents, as certified by the Secretary of State of such Person’s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective
Date, and, (i) if such Person is a corporation, its bylaws in current form, (ii) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (iii) if such Person is a partnership,
its partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto. 

“Outside Director” is defined in Section 7.2. 

“Oxford” is defined in the Preamble hereto. 
 “Oxford Warrant” is that certain Warrant to Purchase Stock dated as of the Effective Date executed by Borrower in favor of Oxford. 

“Patents” are patents, patent applications and like protections, including improvements, divisions, continuations,
renewals, reissues, extensions and continuations in part of the same. 

  
 22 

 “Permitted Indebtedness” is: 

(a) Borrower’s indebtedness to Lenders under this Agreement or the Loan Documents; 

(b) Indebtedness existing on the Effective Date and shown on the Perfection Certificate, including any existing Indebtedness to any
Lender; 
 (c) Subordinated Debt; 
 (d) Indebtedness to trade creditors and with respect to surety bonds and similar obligations incurred in the ordinary course of business; 

(e) Indebtedness secured by Permitted Liens; 
 (f) Indebtedness of Borrower to any Subsidiary and Contingent Obligations of any Subsidiary with respect to obligations of Borrower (provided that the primary obligations are not prohibited hereby), and
Indebtedness of any Subsidiary to any other Subsidiary and Contingent Obligations of any Subsidiary with respect to obligations of any other Subsidiary (provided that the primary obligations are not prohibited hereby); 

(g) Other Indebtedness not otherwise permitted by Section 7.4 not exceeding $50,000 in the aggregate outstanding at any time;

 (h) Extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness
(a) through (g) above, provided that the then outstanding principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be; 

(i) the American Express Facility; 
 (j) Purchase money Indebtedness incurred in connection with the acquisition of pharmaceutical products or the rights related thereto so long as Borrower has raised additional equity financing or
Subordinated Debt from Borrower’s existing or future equity investors specifically for the purpose, and in amount sufficient, to make: (1) all up-front and ongoing contractual payments which would reasonably be expected to become due
thereunder during the term of this Agreement as determined in good faith by Borrower, and (2) the cash needs required under clause (j) of the definition of Permitted Investments; and 

(k) Any real property lease. 
 “Permitted Investments” are: 
 (a) Investments shown on the
Perfection Certificate and existing on the Effective Date; 
 (b)(i) marketable direct obligations issued or unconditionally
guaranteed by the United States or its agency or any state maturing within 1 year from its acquisition, (ii) commercial paper maturing no more than 1 year after its creation and having the highest rating from either Standard &
Poor’s Corporation or Moody’s Investors Service, Inc., (iii) SVB’s certificates of deposit issued maturing no more than 1 year after issue, (iv) any other investments administered through the Lenders and (v) any
Investments permitted by Borrower’s investment policy, as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved by Lenders; 

(c) Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary
course of business and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower’s Board of
Directors; which do not exceed $100,000 in the aggregate in any year, provided that no cash loans under this clause (ii) may be made if an Event of Default is then occurring or would otherwise upon the making thereof; 

  
 23 

 (d) Investments (including debt obligations) received in connection with bankruptcy or
reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business; 

(e) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are
not Affiliates of Borrower, in the ordinary course of business; provided that this paragraph (e) shall not apply to Investments of Borrower in any Subsidiary; 
 (f) Investments in joint ventures or strategic alliances (in the ordinary course of Borrower’s business) consisting of the licensing of technology as permitted by Section 7.1, the
development of technology or the providing of technical support, provided that any cash investments by Borrower do not exceed $50,000 in the aggregate in any fiscal year, provided that no such cash investment may be made if an Event of Default is
then occurring or would otherwise upon the making thereof; 
 (g) Investments pursuant to or arising under currency agreements or
interest rate agreements entered into in the ordinary course of business; 
 (h) Investments consisting of deposit accounts and
securities accounts of Borrower, subject to the compliance by Borrower with the covenant set forth in Section 6.6 hereof; 
 (i) To the extent it is deemed to be an Investment, up-front fees, license fees, milestone payments, royalty payments and other cash payments arising in connection with the acquisition of rights to
intellectual property of a third party, including without limitation, rights to a pharmaceutical product, so long as Borrower has raised additional equity financing or Subordinated Debt from Borrower’s existing or future equity investors
specifically for the purpose, and in amount sufficient, to make: (1) all up-front and ongoing payments which would reasonably be expected to become due thereunder during the term of this Agreement as determined in good faith by Borrower, and
(2) the cash needs required under clause (i) of the definition of Permitted Indebtedness; and 
 (j) Other Investments
not otherwise permitted by Section 7.6 not exceeding $50,000 in the aggregate outstanding at any time. 

“Permitted Liens” are: 
 (a) Liens existing on the Effective Date and shown on the Perfection Certificate or arising under this Agreement or other Loan Documents, including Liens in favor of any Lender; 

(b) Liens for taxes, fees, assessments or other government charges or levies, either not delinquent or being contested in good faith and
for which Borrower maintains adequate reserves on its Books, if they have no priority over any of Lenders’ security interests; 
 (c) Purchase money Liens (and including for purposes of this clause Liens incurred in connection with capital leases) (i) on Equipment acquired or held by Borrower incurred for financing the
acquisition of the Equipment securing no more than Five Hundred Thousand Dollars ($500,000) in the aggregate amount outstanding, or (ii) existing on equipment when acquired, if the Lien is confined to the property and improvements and the
proceeds of the equipment; 
 (d) Leases or subleases and licenses or sublicenses granted in the ordinary course of
Borrower’s business, if the leases, subleases, licenses and sublicenses do not prohibit granting Lenders a security interest; 
 (e) Statutory Liens securing claims or demands of materialmen, mechanics, carriers, repairmen, or other like Liens imposed without the action of such parties arising in the ordinary course of business;
provided they have no priority over any of Lenders’ Liens and the aggregate amount of such Liens does not at any time exceed $50,000; 
 (f) Banker’s liens, rights of setoff and similar Liens incurred on deposits made in the ordinary course of business subject to Borrower’s compliance with Section 6.6 hereof;

  
 24 

 (g) Liens arising from judgments, decrees or attachments in circumstances not constituting
an Event of Default under Sections 8.4 or 8.7; 
 (h) Liens in favor of other financial institutions arising in connection
with Borrower’s deposit accounts or securities accounts held at such institutions to secure payment of fees and similar costs and expenses subject to Borrower’s compliance with Section 6.6 hereof; 

(i) Liens to secure payment for workers’ compensation, employment insurance, old age pensions, social security or other like
obligations incurred in the ordinary course of business, provided they have no priority over any of Lenders’ Liens and the aggregate amount of the Indebtedness secured by such Liens does not at any time exceed $50,000; 

(j) Easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and similar charges or encumbrances
affecting real property not constituting a material adverse effect on the business or condition (financial or otherwise) of Borrower or otherwise materially impairing the conduct of Borrower’s business; 

(k) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties in connection with the
importation of goods; 
 (l) Transfers, licenses or sublicenses permitted under Section 7.1; 

(m) Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described above, but any extension,
renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the then outstanding principal amount of the indebtedness may not increase; and 
 (n) Cash collateral securing the American Express Facility in an aggregate amount not to exceed Four Hundred Fifty Thousand Dollars ($450,000) at any time. 

“Person” is any individual, sole proprietorship, partnership, limited liability company, joint venture, company
association, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

“Prepayment Fee” shall be, for each Growth Capital Advance, an amount equal to: (i) if the prepayment date is on or
before the two year anniversary after the Additional Growth Capital Funding Date, three percent (3.0%) of the outstanding principal balance as of the prepayment date, and (ii) if the prepayment date is more than two years after the
Additional Growth Capital Funding Date, two percent (2.0%) of the outstanding principal balance as of the prepayment date. 

“Proceeds” has the meaning described in the Code as in effect from time to time. 

“Registered Organization” means an organization organized solely under the law of a single state or the United States
and as to which the state or the United States must maintain a public record showing the organization to have been organized. 

“Required Lenders” means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an
“Original Lender”) have not assigned or transferred any of their interests in their respective Growth Capital Advances, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance of the Growth
Capital Advances, or (ii) at any time from and after any Original Lender has assigned or transferred any interest in its Growth Capital Advances, Lenders holding, sixty-six percent (66%) or more of the aggregate outstanding principal
balance of the Growth Capital Advances, plus, in respect of this clause (ii), (a) each Original Lender that has not assigned or transferred any portion of its respective Growth Capital Advances, other than to one or more Affiliates or
Approved Funds of such Lender, and (b) each assignee of an Original Lender provided such assignee was assigned or transferred and continues to hold one hundred percent (100%) of the assigning Original Lender’s interest in the Growth
Capital Advances (in each case in respect of clauses (a) and (b) of this clause (ii), whether or not such Lender is included within the Lenders holding sixty-six percent (66%) of the Growth Capital Advances). For purposes of this
definition only, a Lender shall be deemed to include itself, and any Affiliate or Approved Fund of such Lender. 

  
 25 

 “Responsible Officer” is each of the Chief Executive Officer, President and
Chief Financial Officer of Borrower. 
 “Secured Promissory Note” is defined in Section 2.3.

 “Secured Promissory Note Record” is a record maintained by each Lender with respect to the outstanding
Obligations owed by Borrower to Lender and credits made thereto. 
 “Subordinated Debt” is debt incurred by
Borrower subordinated to Borrower’s debt to Lenders (pursuant to a subordination agreement entered into between the Lenders, the Borrower and the subordinated creditor), on terms acceptable to Lenders. 

“Subsidiary” is any Person, corporation, partnership, limited liability company, joint venture, or any other business
entity of which more than 50% of the voting stock or other equity interests is owned or controlled, directly or indirectly, by the Person or one or more Affiliates of the Person. 

“Supporting Obligation” means a Letter-of-Credit Right, secondary obligation or obligation of a secondary obligor or
that supports the payment or performance of an account, chattel paper, a document, a general intangible, an instrument or investment property. 
 “Surviving Entity” is defined in Section 7.3. 

“SVB” is defined in the Preamble hereto. 
 “SVB Warrant” is that certain Warrant to Purchase Stock dated as of the Effective Date executed by Borrower in favor of SVB. 

“Trademarks” are trademark and service mark rights, registered or not, applications to register and registrations and
like protections, and the entire goodwill of the business of the owner or licensee of such trademark and service mark rights connected with the trademarks and service mark rights. 

“Transfer” is defined in Section 7.1. 

“Warrants” means, collectively, (i) the GECC Warrant, the Oxford Warrant and the SVB Warrant, and (ii) all
other warrants to purchase stock previously issued by Borrower to any Lender. 
 (Signatures are on the following page)

  
 26 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first above
written. 
  

			
	BORROWER:
	
	CADENCE PHARMACEUTICALS, INC.
		
	By:	 	 /s/ William R. LaRue

		 	Name: William R. LaRue
		 	Title: SVP & Chief Financial Officer
	
	LENDERS:
	
	OXFORD FINANCE LLC, as Collateral Agent and as a Lender
		
	By:	 	 /s/ John G. Henderson

		 	Name: John G. Henderson
		 	Title: Vice President & General Counsel
	
	SILICON VALLEY BANK, as a Lender
		
	By:	 	 /s/ D. Michael White

		 	Name: D. Michael White
		 	Title:
	
	GENERAL ELECTRIC CAPITAL CORPORATION, as a Lender
		
	By:	 	 /s/ Peter Gibson

		 	Name: Peter Gibson
		 	Title: Duly Authorized Signatory

 Effective as of December 22, 2011 

  
 27 

 EXHIBIT A 

The Collateral consists of all right, title and interest of Borrower in and to the following: 

All goods, equipment, inventory, contract rights or rights to payment of money, license agreements, franchise agreements, general
intangibles (including payment intangibles), Accounts (including health-care receivables), documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, fixtures, letters of credit
rights (whether or not the letter of credit is evidenced by a writing), commercial tort claims, securities, and all other investment property, financial assets, whether now owned or hereafter acquired, wherever located; all Supporting Obligations
and any and all claims, rights and interests in any of the above and all substitutions for, additions and accessions to and Proceeds thereof. 
 All Letter-Of-Credit Rights (whether or not the letter of credit is evidenced by a writing); and 
 All Borrower’s Books relating to the foregoing and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and
improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing. 
 The Collateral
does not include: 
 (a) Any Intellectual Property. Notwithstanding the foregoing, the Collateral shall include all Accounts,
license and royalty fees and other revenues, proceeds, or income arising out of or relating to any of the Intellectual Property. 
 (b) Any contract, instrument or chattel paper in which the Borrower has any right, title or interest if and to the extent any such contract, instrument or chattel paper includes a provision containing a
restriction on assignment such that the creation of a security interest in the right, title or interest of Borrower therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to
such contract, instrument or chattel paper to enforce any remedy with respect thereto (provided that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such person has otherwise consented to the creation
hereunder of a security interest in such contract, instrument or chattel paper or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the Code, as applicable and as then in effect in any relevant
jurisdiction, or any other applicable law (including the federal bankruptcy code) or principles of equity; provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the Collateral shall include, and
Borrower shall be deemed to have granted a security interest in, all its rights, title and interest in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion
shall in no way be construed so as to limit, impair or otherwise affect Lenders’ unconditional continuing security interest in and to all rights, title and interests of Borrower in or to any payment obligations or other rights to receive monies
due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper). 
 Negative Pledge on Intellectual Property: 
 Except as expressly permitted
under the Loan Agreement, Borrower covenants and agrees that until the full and complete payment of the obligations to Lenders, Borrower will not do any of the following: sell, transfer, assign, mortgage, pledge, lease, grant a security interest in,
or encumber any Intellectual Property, or enter into any agreement, document, instrument or other arrangement (except with or in favor of Lenders) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower from
selling, transferring, assigning, mortgaging, pledging, leasing, granting a security interest in or upon, or encumbering any of Borrower’s Intellectual Property, except as permitted by Section 7.1 of the Loan Agreement. 

Definitions: 
 Capitalized terms, not otherwise defined herein, shall have the meanings given such capitalized terms in the Second Amended and Restated Loan and Security Agreement among Collateral Agent, Lenders and
Borrower dated as of December 22, 2011 (the “Loan Agreement”). 

 EXHIBIT B-1 

Loan Payment/Advance Request Form 
 [See attached] 

 DISBURSEMENT LETTER 
 The undersigned, being the duly elected and acting                    of CADENCE PHARMACEUTICALS, INC.,
a Delaware corporation, with offices located at 12481 High Bluff Drive, Suite 200, San Diego, California 92130 (“Borrower”), does hereby certify to OXFORD FINANCE LLC, (“Oxford” and
“Lender”), as collateral agent (the “Collateral Agent”) in connection with that certain Second Amended and Restated Loan and Security Agreement dated as of December 22, 2011, by and among Borrower, Collateral
Agent and the Lenders from time to time party thereto (the “Loan Agreement”; with other capitalized terms used below having the meanings ascribed thereto in the Loan Agreement) that: 

1. The representations and warranties made by Borrower in Section 5 of the Loan Agreement and in the other Loan Documents are true and correct in
all material respects as of the date hereof. 
 2. No event or condition has occurred that would constitute an Event of Default under the Loan
Agreement or any other Loan Document. 
 3. Borrower is in compliance with the covenants and requirements contained in Sections 4, 6 and 7 of
the Loan Agreement. 
 4. All conditions referred to in Section 3 of the Loan Agreement to the making of the Loan to be made on or about
the date hereof have been satisfied or waived by Collateral Agent. 
 5. No Material Adverse Change has occurred. 

6. The undersigned is a Responsible Officer. 
 [Balance of Page Intentionally Left Blank] 

 7. The proceeds of the Additional Growth Capital Advance shall be disbursed as follows:

  

					
	Disbursement from Oxford:	  			
	 Aggregate Oxford Growth Capital Advances Amount Plus:
	  	$	                	  
	 —Deposit Received
	  	$	                	  
	 Less:
	  			
	 —Amount of Existing Growth Capital Advances
	  	$	(            	) 
	 —Amount of Accrued Interest
	  	$	(            	) 
	 —Amount of Existing Final Payment
	  	$	(            	) 
	 [—Interim Interest
	  	$	(            	)] 
	 —Lender’s Legal Fees
	  	$	(            	)* 
	Net Proceeds due from Oxford:	  	$	                	  
	Disbursement from SVB:	  			
	 Aggregate SVB Growth Capital Advances Amount Plus:
	  	$	                	  
	 —Deposit Received
	  	$	                	  
	 Less:
	  			
	 —Amount of Existing Growth Capital Advances
	  	$	(            	) 
	 —Amount of Accrued Interest
	  	$	(            	) 
	 —Amount of Existing Final Payment
	  	$	(            	) 
	 [—Interim Interest
	  	$	(            	)] 
	Net Proceeds due from SVB:	  	$	                	  
	Disbursement from GECC:	  			
	 Aggregate GECC Growth Capital Advances Amount Plus:
	  	$	                	  
	 —Deposit Received
	  	$	                	  
	 Less:
	  			
	 —Amount of Existing Growth Capital Advances
	  	$	(            	) 
	 —Amount of Accrued Interest
	  	$	(            	) 
	 —Amount of Existing Final Payment
	  	$	(            	) 
	 [—Interim Interest
	  	$	(            	)] 
	 Net Proceeds due from GECC:
	  	$	                	  

 8. The aggregate net proceeds of the Growth Capital Advance shall be transferred to the Designated
Deposit Account as follows: 
  

					
	Account Name:	  	  
	 	.
			
	Bank Name:	  	  
	 	.
			
	Bank Address:	  	  
	 	.
			
	Account Number:	  	  
	 	.

  

	*	Legal fees and costs are through the Effective Date. Post-closing legal fees and costs, payable after the Effective Date, to be invoiced and paid post-closing.

					
			
	ABA Number:	  	  
	 	.

 [Balance of Page Intentionally Left Blank] 

 Dated as of the date first set forth above. 

 

			
	BORROWER:
	  
 CADENCE PHARMACEUTICALS, INC.

		
	By	 	  

	Name:	 	  

	Title:	 	  

	  
 COLLATERAL AGENT AND
LENDER:

	  
 OXFORD FINANCE
LLC

		
	By	 	  

	Name:	 	  

	Title:	 	  

 [Signature Page to Loan Payment/Advance Request Form; Disbursement
Letter] 

 EXHIBIT B-2 

Loan Payment/Advance Request Form 
 DEADLINE FOR SAME DAY PROCESSING IS NOON PACIFIC TIME*

  

			
	Fax To: (415) 856-0810	  	Date:                     

  

							
	LOAN PAYMENT:	 	 	  	 	 	
	 	 	
	 	 	CADENCE PHARMACEUTICALS, INC.	 	
	 		 	
	From Account #                
                                         
               	 		  	To Account #                   
                                         
                	 	
	 (Deposit Account #)
	 		  	 (Loan Account #)
	 	
	Principal $                 
                                         
                      	 		  	and/or Interest $                  
                                         
             	 	
	 		 	
	Authorized Signature:                
                                         
     	 		  	
Phone Number:                        
                                 
	 	
	
Print Name/Title:                     
                                         
       
  
	 	 	  	 	 	

  

							
	LOAN ADVANCE:	 	 	  	 	 	
	  
 Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire.
	 	
	 		 	
	From Account #                
                                         
                	 		  	To Account #                   
                                         
                	 	
	 (Loan Account #)
	 		  	 (Deposit Account #)
	 	
	 		 	
	Amount of Advance $              
                                         
         	 		  	 	 	
	 	
	 All Borrower’s representations
and warranties in the Second Amended and Restated Loan and Security Agreement are true, correct and complete in all material respects on the date of the request for an advance; provided, however, that such materiality qualifier shall not be
applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true,
accurate and complete in all material respects as of such date:
  
	 	
	 		 	
	Authorized Signature:                
                                         
       	 		  	
Phone Number:                        
                                
	 	
	
Print Name/Title:                     
                                         
         
  
	 	 	  	 	 	

  

							
	OUTGOING WIRE REQUEST:	 	 	  	 	 	
	 Complete only if all or a portion
of funds from the loan advance above is to be wired.
  
 Deadline for same
day processing is noon, Pacific Time
	 	
	 		 	
	Beneficiary Name:                
                                         
               	 		  	Amount of Wire: $                 
                                         
      	 	
	Beneficiary Bank:                
                                         
                 	 		  	Account Number:                   
                                         
        	 	
	City and State:                
                                         
                     	 		  	 	 	
	 		 	
	Beneficiary Bank Transit (ABA)#:            
                                  	 		  	Beneficiary Bank Code (Swift, Sort, Chip, etc.):         
         	 	
	 	 		  	 (For International Wire Only)
	 	
	Intermediary Bank:                
                                         
               	 		  	Transit (ABA)
#:                                        
                            	 	
	For Further Credit to:       
                                         
                                         
                                         
                                         
     	 	
	 	
	Special Instruction:         
                                         
                                         
                                         
                                         
       	 	
	By signing below, I (we) acknowledge and agree that my (our) funds transfer
request shall be processed in accordance with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me (us).	 	
	 		 	
	Authorized Signature:                
                                         
       	 		  	2nd
 Signature (if required):                          
                          	 	
	
Print Name/Title:                     
                                         
        
  
	 	 	  	
Print Name/Title:                     
                                         
  
  
	 	

  

					
	
Telephone #:                        
                                        

	 		  	
Telephone #:                        
                                    ]

 EXHIBIT C 

 

			
	TO:	  	OXFORD FINANCE LLC, SILICON VALLEY BANK and GENERAL ELECTRIC CAPITAL CORPORATION
		
	FROM:	  	CADENCE PHARMACEUTICALS, INC.

 The undersigned authorized officer of CADENCE PHARMACEUTICALS, INC. hereby certifies that in accordance with the terms
and conditions of the Second Amended and Restated Loan and Security Agreement between Borrower, Collateral Agent and Lenders (the “Agreement”), 
 (i) Borrower is in complete compliance for the period ending                      with all required
covenants except as noted below and 
 (ii) All representations and warranties of Borrower stated in the Agreement are true and correct as
of the date hereof. Attached are the required documents, if any, supporting our certification(s). The Officer further certifies that these are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied
from one period to the next except as explained in an accompanying letter or footnotes. 
 Please indicate compliance status since the last
Compliance Certificate by circling Yes, No, or N/A under “Complies” column. 
  

													
	  	 	 Reporting Covenant
	 	 Requirement
	 	 	  	Complies
	 1)
	 	 Financial statements
	 	Quarterly within 45 days	 		  	Yes	  	No	  	N/A
							
	 2)
	 	 Annual (CPA Audited) statements
	 	Within 180 days after Fiscal Year End	 		  	Yes	  	No	  	N/A
							
	 3)
	 	 Annual Financial Projections/Budget
	 	FYE within 45 days	 		  	Yes	  	No	  	N/A
							
	 4)
	 	 10-K and 10-Q Filings
	 	Within 5 days after filing with SEC	 		  	Yes	  	No	  	N/A
							
	 5)
	 	 Total amount of Borrower’s cash and cash equivalents
	 		 	$            	  		  		  	
							
	 6)
	 	Total amount of Borrower’s cash and cash equivalents maintained with SVB as specified in Agreement.	 	50%	 	$            	  	Yes	  	No	  	N/A

 Deposit and Securities Accounts (Please list all accounts; attach separate
sheet if additional space needed) 
  

													
	 	 	 Bank
	  	Account Number	  	New Account?	  	Acct Control
Agmt in place?
	 1)
	 		  		  	Yes	  	No	  	Yes	  	No
							
	 2)
	 		  		  	Yes	  	No	  	Yes	  	No
							
	 3)
	 		  		  	Yes	  	No	  	Yes	  	No
							
	 4)
	 		  		  	Yes	  	No	  	Yes	  	No
							
	 5)
	 		  		  	Yes	  	No	  	Yes	  	No
							
	 6)
	 		  		  	Yes	  	No	  	Yes	  	No
		 	 Other Matters
	  		  		  		  		  	
							
		 	Have there been any changes in management?	  		  		  	Yes	  	No	  	
							
		 	Have there been any transfers/sales/disposals/retirement of Collateral or IP?	  		  		  	Yes	  	No	  	
							
		 	Have there been any new or pending claims or causes of action against Borrower?	  		  		  	Yes	  	No	  	
							
		 	Exceptions	  		  		  		  		  	

											
	Please explain any exceptions with	  	  

	 respect to the certification above:
 (If no exceptions exist, state “No
	  	  

	exceptions.” Attach separate sheet if	  	  

	additional space needed.)	  	  

  

													
	  
	  	  
	  		 	LENDERS USE ONLY
	SIGNATURE	  	DATE	  		 		 		 		 	 
	  
	  		  		 	Received by:	 	              
	 	Verified by:	 	
             

	TITLE	  		  		 	Date:	 	              
	 	Date:	 	
             

		  		  		 	Compliance
Status  
	 	 	 	 Yes

 
	 	 No

 

 EXHIBIT D 

[AMENDED AND RESTATED] SECURED PROMISSORY NOTE 
 (Growth Capital Advances) 
  

			
	$        	  	Dated: [DATE]

 FOR VALUE RECEIVED, the undersigned, CADENCE PHARMACEUTICALS, INC. with offices located at 12481 High Bluff Drive, Suite
200, San Diego, CA 92130 (“Borrower”) HEREBY PROMISES TO PAY to the order of [LENDER] (“Lender”) the principal amount of [            ] DOLLARS
($            ) or such lesser amount as shall equal the outstanding principal balance of the Growth Capital Advances made to Borrower by Lender, plus interest on the aggregate unpaid
principal amount of such Growth Capital Advances, at the rates and in accordance with the terms of the Second Amended and Restated Loan and Security Agreement dated December [    ], 2011 by and among Borrower, Oxford Finance LLC,
as Collateral Agent, and the Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”). If not sooner paid, the entire principal amount and all accrued
and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement. Any capitalized term not otherwise defined herein shall have the meaning attributed to such term in the Loan Agreement. 

[This Secured Promissory Note (this “Note”) amends and restates in its entirety, without novation, that certain Growth Capital Advances
Note Secured Promissory Note issued by Borrower to Lender on June 18, 2010 in the original principal face amount of $[            ].] 

Principal, interest and all other amounts due with respect to the Growth Capital Advances, are payable in lawful money of the United States of America to
Lender as set forth in the Loan Agreement and this Note. The principal amount of this Note and the interest rate applicable thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed
on the grid attached hereto which is part of this Note. 
 The Loan Agreement, among other things, (a) provides for the making of secured
Growth Capital Advances by Lender to Borrower, and (b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events. 
 This Note may not be prepaid except as set forth in Section 2.2 (d) and Section 2.2(e) of the Loan Agreement. 
 This Note and the obligation of Borrower to repay the unpaid principal amount of the Growth Capital Advances, interest on the Growth Capital Advances and all other amounts due Lender under the Loan
Agreement is secured under the Loan Agreement. 
 Presentment for payment, demand, notice of protest and all other demands and notices of any
kind in connection with the execution, delivery, performance and enforcement of this Note are hereby waived. 
 Borrower shall pay all
reasonable fees and expenses, including, without limitation, reasonable attorneys’ fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrower’s obligations hereunder not performed when due. 

This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of California. 

The ownership of an interest in this Note shall be registered on a record of ownership maintained by Lender or its agent. Notwithstanding anything else
in this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an interest in the
obligation. Borrower shall be entitled to treat the registered holder of this Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or
interest in this Note on the part of any other person or entity. 
 [Balance of Page Intentionally Left
Blank] 

 IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed by one of its officers thereunto duly
authorized on the date hereof. 
  

	
	BORROWER:
	
	CADENCE PHARMACEUTICALS, INC.
	
	By                             
                                         
                           
	Name:                             
                                         
                    
	Title:                            
                                         
                       
	
	[LENDER:
	                             
                                         
                                 
	By                             
                                         
                           
	Name:                             
                                         
                    
	Title:                            
                                         
                      ]

 LOAN INTEREST RATE AND PAYMENTS OF PRINCIPAL 

 

									
	 Date
	  	 Principal

Amount
	  	 Interest Rate
	  	 Scheduled

Payment Amount
	  	 Notation By

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]